Document:

PartnerRe Ltd. 2003 Non-Employee Directors Plan

 Exhibit 10.1 
  
 PARTNERRE LTD. 2003 NON-EMPLOYEE DIRECTORS STOCK PLAN 
  
 Amended and Restated 10 February 2005 
  
 Section 1. Purpose. 
  
 The PartnerRe Ltd. 2003 Non-Employee Directors Stock Plan is designed to enhance the ability of the Company to attract, retain and reward outside
directors of the Company with equitable and competitive compensation opportunities and to allow outside directors of the Company to share in the stock ownership of the Company. 
  
 Section 2. Definitions. 
  
 As used in the Plan, the following terms shall have the meanings set forth below: 
  
 (a) “Affiliate” shall mean (i) any entity that, directly or indirectly, is controlled by the Company and
(ii) any entity in which the Company has a significant equity interest, in either case as determined by the Committee. 
  
 (b) “Alternative Award” shall mean an Award granted pursuant to Section 10. 
  
 (c) “Award” shall mean any Option, award of Restricted Shares or Restricted Share Units, Alternative Award
or Other Share-Based Award granted under the Plan. 
  
 (d)
“Award Agreement” shall mean any written agreement, contract or other instrument or document evidencing any Award granted under the Plan, which may, but need not, be executed or acknowledged by a Participant. 
  
 (e) “Board” shall mean the board of directors of the
Company. 
  
 (f) “Change in Control” shall occur
when (i) any “person” within the meaning of Section 14(d) of the Exchange Act, other than the Company, a Subsidiary or any employee benefit plan(s) sponsored by the Company or any Subsidiary, is or becomes the “beneficial owner”
(as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of forty percent (40%) or more of the then outstanding Common Stock; (ii) individuals who constitute the Board on the effective date of this Plan cease for any reason to
constitute at least a majority thereof, provided that any person becoming a director subsequent to the effective 

 
date of this Plan, whose election, or nomination for election by the Company’s shareholders, was on the recommendation or with the approval of at least
two-thirds of the directors comprising the Board on the effective date of this Plan (either by a specific vote or by approval of the proxy statement of the Company in which such person is named as a nominee for director, without objection to such
nomination) shall be, for purposes of this clause (ii), considered as though such person were a member of the Board on the effective date of this Plan; and provided further that, notwithstanding the foregoing, no such individual whose initial
assumption of office occurs as a result of either an actual or threatened election contest (as such terms are used in Rule 14a-11 or Regulation 14A promulgated under the Exchange Act) or other actual or threatened solicitation of proxies or consents
by or on behalf of an individual, corporation, partnership, group, associate or other entity or “person” other than the Board shall in any event be considered to be a director in office on the effective date of this Plan or a member of
such necessary majority; (iii) any plan or proposal for the liquidation of the Company is adopted by the shareholders of the Company; (iv) all or substantially all of the assets of the Company are sold, liquidated or distributed (in one or a series
of related transactions); or (v) there occurs a reorganization, merger, consolidation or other corporate transaction involving the Company (a “Transaction”), other than with a wholly-owned Subsidiary and other than a merger or
consolidation that would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or ultimate
parent thereof) more than 50% of the combined voting power of the voting securities of the Company or such surviving entity, or the ultimate parent thereof, outstanding immediately after such Transaction. 
  
 (g) “Code” shall mean the U.S. Internal Revenue Code of
1986, as amended from time to time. 
  
 (h)
“Committee” means the Committee appointed by the Board to administer the Plan. 
  
 (i) “Company” shall mean PartnerRe Ltd., a Bermuda corporation together with any successor thereto. 
  
 (j) “Event” shall mean any of the corporate transactions or
events described in Section 6(d). 
  
 (k) “Exchange
Act” shall mean the U.S. Securities Exchange Act of 1934, as amended. 
  
 (l) “Exercise Price” shall mean the purchase price per Share under the terms of an Option as determined pursuant to Section 7 of the Plan. 

 (m) “Expiration Date” shall mean the final date of the term of an Option, which shall be
fixed by the Committee pursuant to Section 7(b) of the Plan. 
  
 (n) “Fair Market Value” with respect to a Share shall mean, (i) if the Shares are listed on a national securities exchange, the mean between the highest and lowest sale prices reported as having occurred on the primary
exchange with which the Shares are listed and traded on the date prior to such date, or, if there is no such sale on that date, then on the last preceding date on which such a sale was reported, or (ii) if the Shares are not listed on any national
securities exchange but are quoted in the National Market System of the National Association of Securities Dealers Automated Quotation System on a last sale basis, the average between the high bid price and low ask price reported on the date prior
to such date, or, if there is no such sale on that date then on the last preceding date on which such a sale was reported. If the Shares are not quoted on NASDAQ-NMS or listed on an exchange, or representative quotes are not otherwise available, the
Fair Market Value shall mean the amount determined by the Board in good faith to be the fair market value per Share, on a fully diluted basis. 
  
 (o) “Option” shall mean the right to purchase Shares granted under Section 7. 
  
 (p) “Other Share-Based Award” shall mean any right granted
under Section 9. 
  
 (q) “Outside Director” shall
mean any director of the Company who is not an employee of the Company or any of its Affiliates. 
  
 (r) “Participant” shall mean an individual granted an Award under the Plan. 
  
 (s) “Person” shall mean an individual, corporation, partnership, limited partnership, syndicate, person
(including, without limitation, a “person” as defined in Section 13(d)(3) of the Exchange Act), trust, association or entity or government, political subdivision, agency or instrumentality of a government, but excluding any of the Company,
any Subsidiary or any employee benefit plan sponsored or maintained by the Company or any Subsidiary. 
  
 (t) “Plan” shall mean this PartnerRe Ltd. 2003 Non-Employee Directors Stock Plan, as may be amended from time to time. 
  
 (u) “Plan Year” shall mean, with respect to an Outside
Director, the period commencing at the time of election of directors at an annual meeting of shareholders of the Company (or the election of a class of directors if the Company then has a classified board), or such Outside Director’s initial
election or appointment to the Board if not at such an annual meeting of shareholders, and continuing until the close of business of the day preceding the next annual meeting of shareholders of the Company. 

 (v) “Policies” shall mean policies established from time to time by the Board as set
forth in Section 4. 
  
 (w) “Restricted Share”
shall mean any Share granted under Section 8. 
  
 (x)
“Restricted Share Unit” shall mean a contractual right granted under Section 8 that is denominated in Shares, each of which represents a right to receive the value of a Share (or a percentage of such value, which percentage may be
higher than 100%) upon the terms and conditions set forth in the Plan and the applicable Award Agreement. 
  
 (y) “Retainer Fees” shall mean all retainer fees including, without limitation, meeting or chair fees, payable to an Outside Director in
his or her capacity as such for services to the Board. 
  
 (z)
“Securities Act” shall mean the U.S. Securities Act of 1933, as amended. 
  
 (aa) “Shares” shall mean common shares of the Company, $1.00 par value. 
  
 (bb) “Subsidiary” shall mean any corporation of which a majority of the outstanding voting shares or voting power is beneficially owned
directly or indirectly by the Company and otherwise as provided in Section 86 of the Companies Act 1981 of Bermuda. 
  
 Section 3. Eligibility. 
  
 All Outside Directors shall be eligible to receive Awards under the Plan. 
  
 Section 4. Outside Director Awards. 
  
 (a) Awards shall be granted to Outside Directors in accordance with Policies1 established from time to time by the Board specifying (i) the classes of directors (if the Company then has a classified board) to be granted such Awards; (ii)
the type or types of Awards to be granted to Participants under the Plan; (iii) the number of Shares to be covered by (or with respect to which payments, rights, or other matters are to be calculated in connection with) Awards and (iv) the time(s)
at which such Awards shall be granted. 

	1	Note that the existing Policy should be filed as an exhibit to the 10K, and any change in the Policy, or adoption of a new Policy would be required to be reported on
Form 8K. 

 (b) All decisions of the Board and of the Committee shall be final, conclusive and binding upon all
parties, including the shareholders and the Participants. 
  
 (c)
Notwithstanding the foregoing, the maximum number of Shares to which all Awards granted to any Outside Director in a single Plan Year may relate shall not exceed 12,000 for the Chairman or 8,500 for any Outside Director. 
  
 Section 5. Administration. 
  
 (a) The Plan shall be administered by the Committee. All actions by the
Committee shall be subject to and consistent with the Policies. The Committee may issue rules and regulations for administration of the Plan. It shall meet at such times and places as it may determine. 
  
 (b) Subject to the terms of the Plan, Policies and applicable law, the
Committee shall have full power and authority to: (i) determine the terms and conditions of any Award; (ii) determine whether, to what extent, and under what circumstances Awards may be settled or exercised in cash, Shares, other securities, other
Awards, or other property, or canceled, forfeited or suspended, and the method or methods by which Awards may be settled, exercised, canceled, forfeited or suspended; (iii) determine whether, to what extent, and under what circumstances cash,
Shares, other securities, other Awards, other property, and other amounts payable with respect to an Award under the Plan shall be deferred either automatically or at the election of the holder thereof or of the Committee; (iv) interpret and
administer the Plan and any instrument or agreement relating to, or Award made under, the Plan; (v) establish, amend, suspend or waive such rules and regulations and appoint such agents as it shall deem appropriate for the proper administration of
the Plan; (vi) determine whether and to what extent Awards should comply or continue to comply with any requirement of statute or regulation; (vii) correct any defect or supply any omission or reconcile any inconsistency in the Plan in the manner
and to the extent the Committee decides necessary or desirable; and (viii) make any other determination and take any other action that the Committee deems necessary or desirable for the administration of the Plan. 
  
 Section 6. Shares Available for Awards. 
  
 (a) Subject to adjustment as provided below, the number of Shares available
for issuance under the Plan shall be 500,000. 
  
 (b) If, after
the effective date of the Plan, any Shares covered by an Award, or to which such an Award relates, terminate, lapse or are forfeited or cancelled, then the Shares covered by such Award, or to which such Award relates, to the extent of any such
forfeiture or termination, shall again be, or shall become, available for issuance under the Plan. 

 (c) Any Shares delivered pursuant to an Award will consist of newly issued Shares. 
  
 (d) In the event that the Committee shall determine that any dividend or
other distribution (whether in the form of cash, Shares, other securities, or other property), recapitalization, share split, reverse share split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase or exchange of
Shares or other securities of the Company, issuance of warrants or other rights to purchase Shares or other securities of the Company, or other similar corporate transaction or event affects the Shares such that an adjustment is determined by the
Committee to be appropriate in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan, then the Committee shall, in such manner as it may deem equitable, adjust any or all of (i)
the number and type of Shares (or other securities or property) which thereafter may be made the subject of Awards, including without limitation the Share limits set forth in Section 4(c) and Section 6(a), (ii) the number and type of Shares (or
other securities or property) subject to outstanding Awards, and (iii) the grant, purchase, or Exercise Price with respect to any Award or, if deemed appropriate, make provision for a cash payment to the holder of an outstanding Award; provided,
however, that the number of Shares subject to any Award denominated in Shares shall always be a whole number. 
  
 Section 7. Options. 
  
 Options granted under the Plan shall be, as determined by the Committee, non-qualified share options for U.S. federal income tax purposes (or other types
of Options in jurisdictions outside the United States), as evidenced by the related Award documents, and shall be subject to the foregoing and the following terms and conditions and to such other terms and conditions, not inconsistent with the
provisions of the Plan and the Policies, as the Committee shall determine: 
  
 (a) Exercise Price. The Exercise Price per Share under an Option shall be determined by the Committee; provided, however, such Exercise Price shall not be less than the Fair Market Value of a Share on
the date of grant of such Option. 
  
 (b) Term. The term of
each Option shall be fixed by the Committee; in no event, however, shall the period for exercising an Option extend more than 10 years from the date of grant. 
  

(c) Payment for Shares. Payment for Shares acquired pursuant to Options granted hereunder shall be made in full upon exercise of the Options (i)
in immediately available funds in United States dollars, by wire transfer, certified or bank cashier’s check; (ii) by surrender to the Company of Shares that have either been (A) held by the Participant for at least six-months, or (B) acquired
from a person other than the Company, and have a Fair Market Value equal to 

 
such aggregate Exercise Price; (iii) by delivering to the Company a copy of irrevocable instructions to a stockbroker to deliver promptly to the Company an
amount of sale or loan proceeds sufficient to pay the aggregate Exercise Price; (iv) by any combination of (i), (ii), or (iii) above; or (v) by any other means approved by the Committee. 
  
 Section 8. Restricted Shares and Restricted Share Units. 
  
 (a) The Committee is hereby authorized to grant, or to provide for the
automatic grant of, Awards of Restricted Shares and Restricted Share Units pursuant to the Policies to Participants. 
  
 (b) Restricted Shares and Restricted Share Units shall be subject to such restrictions as the Committee may impose (including, without limitation, any
limitation on the right to vote a Restricted Share or the right to receive any dividend or other right or property), which restrictions may lapse, be lifted or waived separately or in combination at such time or times, in such installments or
otherwise, as the Committee may deem appropriate. 
  
 (c) Any
Restricted Share granted under the Plan may be evidenced in such manner as the Committee may deem appropriate including, without limitation, book-entry registration or issuance of a share certificate or certificates. In the event any share
certificate is issued in respect of Restricted Shares granted under the Plan, such certificate shall be registered in the name of the Participant and shall bear an appropriate legend referring to the terms, conditions, and restrictions applicable to
such Restricted Shares. During the applicable restricted period, such certificates shall remain in the custody of the Company or its agent. 
  
 (d) Except as otherwise determined by the Committee pursuant to the Policies whether in an Award Agreement or otherwise, upon termination of a
Participant’s service (as determined under criteria established by the Committee) for any reason during the applicable restriction period, all Restricted Shares and all Restricted Share Units still, in either case, subject to restriction shall
be forfeited. 
  
 Section 9. Other Share-Based Awards.

  
 The Committee is hereby authorized to grant, or to provide
for the automatic grant of, such other Awards (including, without limitation, stock appreciation rights and rights to dividends and dividend equivalents) that are denominated or payable in, valued in whole or in part by reference to, or otherwise
based on or related to, Shares (including, without limitation, securities convertible into Shares) as are deemed by the Committee to be consistent with the purposes of the Plan and the Policies. Subject to the terms of the Plan and the Policies, the
Committee shall determine the terms and conditions of such Awards. Shares or other securities delivered pursuant to a purchase right granted under this 

 
Section 9 shall be purchased for such consideration, which may be paid by such method or methods and in such form or forms, including, without limitation,
cash, Shares, other securities, other Awards, or other property, or any combination thereof, as the Committee shall determine, the value of which consideration, as established by the Committee, shall, not be less than the Fair Market Value of such
Shares or other securities as of the date such purchase right is granted. 
  
 Section 10. Receipt of Alternative Awards in Lieu of Retainer Fees. 
  
 If and to the extent provided by the Policies, a Participant may elect to receive up to 100% of his or her Retainer Fees in Alternative Awards which may
be Shares, Restricted Share Units, Options or other Awards, subject to such terms and conditions as the Committee shall determine. 
  
 Section 11. General Provisions Applicable to Awards. 
  
 (a) Awards shall be granted for no cash consideration or for such minimal consideration as may be required by applicable law. 
  
 (b) Awards may be granted either alone or in addition to or in tandem with
any other Award or any award granted under any other plan of the Company. Awards granted in addition to or in tandem with other Awards, or in addition to or in tandem with awards granted under any other plan of the Company, may be granted either at
the same time as or at a different time from the grant of such other Awards or awards. 
  
 (c) Subject to the terms of the Plan and the Policies, payments or transfers to be made by the Company upon the grant, exercise or payment of an Award may be made in such form or forms as the Committee shall determine
including, without limitation, cash, Shares, other securities, other Awards, or other property, or any combination thereof, and may be made in a single payment or transfer, in installments, or on a deferred basis, in each case in accordance with
rules and procedures established by the Committee. Such rules and procedures may include, without limitation, provisions for the payment or crediting of reasonable interest on installment or deferred payments or the grant or crediting of dividend
equivalents in respect of installment or deferred payments. 
  
 (d) No Award and no right under any such Award, shall be assignable, alienable, saleable or transferable by a Participant otherwise than by will or by the laws of descent and distribution (or in the case of Awards that are forfeited or
canceled, to the Company); provided, however, that, if so determined by the Committee, a Participant may, in the manner established by the Committee, designate a beneficiary or beneficiaries to exercise the rights of the Participant, and to
receive any property distributable, with respect to any Award upon the death of the Participant. Each Award, and each right under any Award, shall be exercisable during the Participant’s lifetime only by the Participant or, if 

  

 
permissible under applicable law, by the Participant’s guardian or legal representative. No Award and no right under any such Award, may be pledged,
alienated, attached, or otherwise encumbered, and any purported pledge, alienation, attachment or encumbrance thereof shall be void and unenforceable against the Company. 
  
 (e) Notwithstanding Section 11(d) to the contrary, Awards may be transferred to family members or trusts during the lifetime
of the Participant, and may be exercised by such transferees in accordance with the terms of such Award, but only if and to the extent such transfers are permitted by the Committee, subject to any terms and conditions which the Committee may impose
thereon (including limitations the Committee may deem appropriate in order that offers and sales under the Plan will meet applicable requirements of registration forms under the Securities Act specified by the Securities and Exchange Commission). A
beneficiary, transferee, or other person claiming any rights under the Plan from or through any Participant shall be subject to all terms and conditions of the Plan and any Award document applicable to such Participant, except as otherwise
determined by the Committee, and to any additional terms and conditions deemed necessary or appropriate by the Committee. 
  
 (f) All certificates for Shares or other securities delivered under the Plan pursuant to any Award or the exercise thereof shall be subject to such stop
transfer orders and other restrictions as the Committee may deem advisable under the Plan or the rules, regulations, and other requirements of the Securities and Exchange Commission, any stock exchange upon which such Shares or other securities are
then listed, and any applicable Federal or state securities laws, and the Committee may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions. 
  
 (g) Except to the extent specifically provided to the contrary in any Award
Agreement and subject to Section 12(e), upon a Change in Control, all Awards shall become fully vested and exercisable, and any restrictions applicable to any Award shall automatically lapse. 
  
 Section 12. Amendment and Termination. 
  
 (a) Except to the extent prohibited by applicable law and unless otherwise
expressly provided in an Award Agreement or in the Plan, the Board may amend, alter, suspend, discontinue, or terminate the Plan or any portion thereof at any time; provided, however, that no such amendment, alteration, suspension,
discontinuation or termination shall be made without (i) shareholder approval if such approval is necessary to comply with any tax or regulatory requirement for which or with which the Board deems it necessary or desirable to qualify or comply or
(ii) the consent of the affected Participant, if such action would adversely affect the rights of such Participant under any outstanding Award. Notwithstanding anything to the contrary herein, the Committee may 

  

 
amend the Plan in such manner as may be necessary to enable the Plan to achieve its stated purposes in any jurisdiction in a tax-efficient manner and in
compliance with local rules and regulations. [Without limiting the generality of the foregoing, if the implementation of any provision of the Plan or any Award would cause any Outside Director to incur adverse tax consequences under Section 409A of
the Code, the implementation of such provision shall be delayed until the first time at which the provision’s implementation would not cause adverse tax consequences under such Section 409A.] 
  
 (b) The Committee may waive any conditions or rights under, amend any terms
of, or amend, alter, suspend, discontinue or terminate, any Award theretofore granted, prospectively or retroactively, without the consent of any relevant Participant or holder or beneficiary of an Award, provided, however, that no such
action shall impair the rights of any affected Participant or holder or beneficiary under any Award theretofore granted under the Plan; and provided further that, except as provided in Section 6(d), no such action shall reduce the exercise
price of any Option established at the time of grant thereof. 
  
 (c) The Committee may, in its sole discretion, amend, or otherwise modify, without Board or shareholder approval, the terms of the Plan or Awards; provided that such amendment or other modification shall not increase the total number
of shares reserved for purposes of the Plan without the approval of the shareholders of the Company. 
  
 (d) The Committee shall be authorized to make adjustments in the terms and conditions of, and the criteria included in, Awards in recognition of unusual
or nonrecurring events (including, without limitation, an Event affecting the Company, or the financial statements of the Company, or of changes in applicable laws, regulations or accounting principles), whenever the Committee determines that such
adjustments are appropriate in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan. 
  
 (e) In connection with a Change in Control or an Event, the Committee may, in its discretion (i) cancel any or all outstanding Awards under the Plan in
consideration for payment to the holder of each such cancelled Award of an amount equal to the portion of the consideration that would have been payable to such holder pursuant to such transaction if such Award had been fully vested and exercisable,
and had been fully exercised, immediately prior to such transaction, less the exercise price if any that would have been payable therefor, or (ii) if the net amount referred to in clause (i) would be negative, cancel such Award for no consideration
or payment of any kind. Payment of any amount payable pursuant to the preceding sentence may be made in cash and/or securities or other property in the Committee’s discretion. 

 Section 13. Miscellaneous. 
  
 (a) No Participant shall have any claim to be granted any Award under the Plan except as otherwise provided in Section 7,
and there is no obligation for uniformity of treatment of Participants or holders or beneficiaries of Awards under the Plan. The terms and conditions of Awards need not be the same with respect to each recipient. 
  
 (b) Nothing contained in the Plan shall prevent the Company from adopting or
continuing in effect other or additional compensation arrangements, and such arrangements may be either generally applicable or applicable only in specific cases. 
  
 (c) The grant of an Award shall not be construed as giving a Participant the right to be retained in the service of the
Company. Further, the Board may at any time terminate the services of a Participant, free from any liability, or any claim under the Plan, unless otherwise expressly provided in the Plan or in any Award Agreement or in any other agreement binding
the parties. 
  
 (d) If any provision of the Plan or any Award is
or becomes or is deemed to be invalid, illegal, or unenforceable in any jurisdiction, or as to any person or Award, or would disqualify the Plan or any Award under any law deemed applicable by the Committee, such provision shall be construed or
deemed amended to conform to applicable laws, or if it cannot be so construed or deemed amended without, in the determination of the Committee, materially altering the intent of the Plan or the Award, such provision shall be stricken as to such
jurisdiction, person or Award, and the remainder of the Plan and any such Award shall remain in full force and effect. 
  
 (e) Neither the Plan nor any Award shall create or be construed to create a trust or separate fund of any kind or a fiduciary relationship between the
Company and a Participant or any other person. To the extent that any person acquires a right to receive payments from the Company pursuant to an Award, such right shall be no greater than the right of any unsecured general creditor of the Company.

  
 (f) No fractional Shares shall be issued or delivered pursuant
to the Plan or any Award, and the Committee shall determine whether cash, other securities or other property shall be paid or transferred in lieu of any fractional Shares, or whether such fractional Shares or any rights thereto shall be canceled,
terminated or otherwise eliminated. 
  
 Section 14. Effective
Date of Plan. 
  
 The Plan shall be effective as of the date
of its approval by the shareholders of the Company. 

 Section 15. Term of the Plan. 
  
 This Plan shall have a term of ten Plan Years, beginning on the effective date of the Plan. No Award shall be granted under
the Plan after the conclusion of the tenth Plan Year. However, unless otherwise expressly provided in the Plan or in an applicable Award Agreement, any Award theretofore granted may extend beyond such date, and the authority of the Committee to
amend, alter, adjust, suspend, discontinue, or terminate any such Award, or to waive any conditions or rights under any such Award, and the authority of the Board to amend the Plan, shall extend beyond such date. 
  
 Section 16. Governing Law. 
  
 The Plan shall be governed by and construed in accordance with the laws of
Bermuda without regard to conflicts of laws.Confidential

           MANUFACTURING, COMMERCIALIZATION AND DEVELOPMENT AGREEMENT

      THIS AGREEMENT is made this 25th day of February, 2005, to be effective as
of the Effective Date, by and among Hospira, Inc., a Delaware corporation having
its principal place of business at 275 North Field Drive, Lake Forest, Illinois
60045 ("Hospira"), and ICU Medical, Inc., a Delaware corporation having its
principal place of business at 951 Calle Amanecer, San Clemente, California
92673 ("ICU").

                                    RECITALS

      A. ICU and Hospira have entered into that certain Asset Purchase Agreement
dated as of February 25, 2005 (the "Asset Purchase Agreement"), which ICU
contemplates assigning to NEWCO, pursuant to which Hospira is transferring to
ICU certain of its assets related to the manufacture of the Transferred Products
and Transferred Components (each as defined below).

      B. Hospira and ICU wish to enter into an arrangement whereby ICU will
manufacture the Transferred Components and Transferred Products for Hospira and
Hospira will (i) incorporate certain Transferred Components into certain
products to be marketed and sold by Hospira, and (ii) market and sell the
Transferred Products with certain technical assistance from ICU, all on the
terms contained herein. The Transferred Products and the Transferred Components
together comprise the "SLC Products," as such term is defined in the Asset
Purchase Agreement.

      1 C. Hospira and ICU also wish to enter into an arrangement whereby
Hospira will manufacture Specified Components (as defined below) for ICU and ICU
will incorporate such Specified Components into certain of the Transferred
Products and Transferred Components prior to selling such Transferred Products
or Transferred Components to Hospira.

      D. Hospira and ICU also wish to engage in the joint development of new
products on the terms contained herein and to enter into certain agreements with
respect to new products developed by Hospira or ICU individually.

      NOW THEREFORE, in consideration of the mutual covenants and agreements
contained herein, and upon the terms and subject to the conditions set forth
below, Hospira and ICU hereby agree as follows:

                            ARTICLE 1 - DEFINITIONS

      1.1 Certain Definitions. The following words and phrases, when used
herein, shall have the meanings set forth or referenced below:

      "Act" shall mean the United States Food, Drug and Cosmetic Act, as
amended, and all regulations promulgated thereunder.

      "ADR" shall have the meaning set forth in Section 14.4.

<PAGE>

                                                                    Confidential

      "Affiliate" shall mean with respect to any Person, another Person that
directly or indirectly, through one or more intermediaries, controls, is
controlled by, or is under common control with, such first Person. For purposes
of this definition, "control" as applied to any Person means the possession,
directly or indirectly, of the power to direct or cause the direction of the
management and policies of that Person, whether through the ownership of voting
securities, by contract, or otherwise.

      "Asset Purchase Agreement" shall have the meaning set forth in the
Recitals.

      "Audit Rights" shall mean the rights of a Party to select an independent
certified public accountant reasonably acceptable to the other Party to inspect,
during normal business hours and upon at least 10 Business Days' notice to such
other Party, the applicable records of such other Party to confirm the accuracy
of its calculations or compliance with specific provisions of this Agreement
that provide for such rights. The determination of the independent certified
public accountant shall be binding on the Parties.

      "Business Day" shall mean any day other than a day which is a Saturday or
Sunday or other day on which commercial banks in Chicago, Illinois are
authorized or required to remain closed.

      "cGMPs" shall mean all current and future good manufacturing practices and
quality systems regulations promulgated by any applicable Regulatory Authority
in a country in which the applicable Product is or will be sold, to the extent
applicable to such Product, including those promulgated by the FDA under 21
C.F.R. Part 820.

      "Catheters" shall mean those Transferred Products identified on Exhibit
1.1C as Catheters.

      1 "Confidential Information" shall mean (i) any and all technical data,
information, materials, trade secrets and other know-how currently owned by or
hereafter developed by, on behalf of, or derived either directly or indirectly
from either Party or its Affiliates, which relates to a Product, its
development, manufacture, promotion, marketing, distribution, sale or use, (ii)
any and all financial data and information relating to the business of either of
the Parties or of their Affiliates, which a Party or its Affiliates discloses to
the other Party or its Affiliates, (iii) the Specifications and all amendments
thereto, and (iv) the terms and conditions of this Agreement. If disclosed
orally or visually, such information shall be considered "Confidential
Information" only if it is identified as confidential at the time of disclosure
and is summarized in a writing to the receiving Party within 30 days of such
disclosure and identified as "Confidential." Notwithstanding the foregoing, the
information described above shall not be "Confidential Information" if it:

            (a) is known to the receiving Party or any of its Affiliates at the
time of the disclosure, as evidenced by written records;

            (b) is disclosed to the receiving Party or any of its Affiliates by
a Third Party not bound by a confidentiality or similar agreement to hold such
information in confidence;

                                       2
<PAGE>

                                                                    Confidential

            (c) becomes patented, published or otherwise part of the public
domain through no fault of the receiving Party or any of its Affiliates;

            (d) is independently developed by or for the receiving Party or any
of its Affiliates without use of Confidential Information, as evidenced by
written records;

            (e) is required by applicable Laws to be disclosed; provided,
however, that no disclosure shall be made by a Party pursuant to this clause
unless prior notice is given to the other Party and such other Party has a
reasonable opportunity to limit such disclosure or take appropriate protective
precautions relating to such disclosure; or

            (f) is necessary to disclose it to prosecute patent rights, obtain
Regulatory Approvals for the Products, or manufacture, market, sell or
distribute the Products pursuant to this Agreement; provided, however, that no
disclosure shall be made by a Party pursuant to this clause unless prior notice
is given to the other Party and such other Party has a reasonable opportunity to
limit such disclosure or take appropriate protective precautions relating to
such disclosure.

      "Contract Year" shall mean a calendar year during the Term, except that
the first Contract Year shall commence on the Effective Date and end on December
31, 2005.

      "Cover Costs" shall have the meaning set forth in Section 3.2(d).

      "Custom Product" shall mean any Product specifically designed, configured
or packaged in response to an individual customer request.

      "Customer Supply Agreements" shall have the meaning set forth in Section
3.2(d).

      "Delivery Date" means the date for delivery of any Product as specified in
the applicable Purchase Order in accordance with the terms of this Agreement.

      "Development Spending" shall have the meaning set forth in Section 7.1(a).

      "Effective Date" shall mean the Closing Date, as defined in the Asset
Purchase Agreement.

      1 "Facility" shall mean the manufacturing facility located at 4455
Atherton Drive, Salt Lake City, Utah.

      "FDA" shall mean the United States Food and Drug Administration and any
successor agency thereto.

      "Field Correction" shall have the meaning set forth in Section 4.3.

                                       3
<PAGE>

                                                                    Confidential

      "GAAP" shall mean United States generally accepted accounting principles
consistently applied from period to period and throughout any period in
accordance with the applicable Party's past practices.

      "Hospira Change of Control Event" shall mean (a) any transaction or series
of transactions that causes a Third Party to own, directly or indirectly, at
least 50% of the outstanding voting securities of Hospira or to be the surviving
corporation in a merger with Hospira; (b) as a result of or in connection with a
contested election of Hospira directors pursuant to a proxy fight for control of
the company, persons who were directors immediately before the election cease to
constitute a majority; or (c) the assignment, sale, transfer, spin-off, lease or
other disposition to a Third Party of all or substantially all of the assets of
Hospira or of the Critical Care business of Hospira.

      "Hospira Derivative Product" shall mean any new product developed or
acquired by Hospira that is derived from Confidential Information shared with
Hospira by ICU.

      "Hospira Marks" shall mean the corporate names "Hospira" and "Hospira,
Inc." and the trademarks, tradenames, service marks and logos of Hospira.

      "ICU Change of Control Event" shall mean: (a) any transaction or series of
transactions that causes a Third Party to own, directly or indirectly, at least
50% of the outstanding voting securities of ICU or the surviving corporation in
a merger with ICU; (b) as a result of or in connection with a contested election
of ICU directors pursuant to a proxy fight for control of the company, persons
who were directors immediately before the election cease to constitute a
majority; or (c) the assignment, sale, transfer, spin-off, lease or other
disposition to a Third Party of all or substantially all of the assets of ICU or
of the assets associated with this Agreement.

      "ICU Derivative Product" shall mean any new product developed or acquired
by ICU that is derived from the technology, know-how or Confidential Information
transferred to or shared with ICU by Hospira.

      "ICU Marks" shall mean the corporate names "ICU," "ICU Medical" and "ICU
Medical, Inc." and the trademarks, tradenames, service marks and logos of ICU.

      "including" shall mean "including without limitation."

      "ISO" shall mean International Standards Organization.

      "Laws" shall mean all national, international, federal, state and local
laws, statutes, regulations and guidelines, including cGMPs.

      "Liabilities" shall have the meaning set forth in Section 11.1.

      "MSDSs" shall have the meaning set forth in Section 3.6(e).

      "Newco" shall have the meaning set forth in the Asset Purchase Agreement.

                                       4
<PAGE>

                                                                    Confidential

      "New Hospira Competitive Product" shall mean any new product (other than a
New Joint Product or Hospira Derivative Product) developed or acquired by
Hospira independent of this Agreement, and without the use of Confidential
Information shared with Hospira by ICU, that could reasonably be expected to
reduce the sales of a Transferred Product by 10% or more. Notwithstanding the
foregoing, New Hospira Competitive Products shall not include any product for
which Hospira does not acquire manufacturing rights.

      "New ICU Competitive Product" shall mean any new product (other than a New
Joint Product or an ICU Derivative Product) developed or acquired by ICU
independent of this Agreement, and without the use of technology, know-how or
Confidential Information transferred to or shared with ICU by Hospira, that
could reasonably be expected to reduce the sales of a Transferred Product by 10%
or more. Notwithstanding the foregoing, New ICU Competitive Products shall not
include any products for which ICU does not acquire marketing, sales or
distribution rights.

      "New Joint Product" shall mean any of the following:

            (a) a new product or an improvement or modification of a Transferred
Product or Transferred Component, in each case funded in whole or in part by the
Development Spending;

            (b) an ICU Derivative Product or Hospira Derivative Product that the
Parties designate in writing as a New Joint Product; or

            (c) a product which results from any future improvements or
modifications to the Specifications in accordance with Section 3.1 for the
products described in subsections (a) or (b).

      "Party" shall mean any of ICU, Newco or Hospira and their respective
successors and permitted assigns, and "Parties" shall mean ICU, Newco and
Hospira and their respective successors and permitted assigns.

      "Person" means an individual, partnership, corporation, business trust,
limited liability company, limited liability partnership, joint stock company,
trust, the executors, administrators or other legal representative of an
individual in such capacity, unincorporated association, joint venture, a
government (or any agency or department of any government) or any other entity.

      "Product" shall mean (i) any Transferred Product, (ii) any Transferred
Component, (iii) any New Joint Product, or (iv) any New ICU Competitive Product
or New Hospira Competitive Product that ICU has agreed in writing to manufacture
and sell to Hospira, and Hospira has agreed in writing to purchase from ICU, in
accordance with Article 8.

      "Purchase Order" shall have the meaning set forth in Section 2.2(a).

      "Regulatory Approval" shall mean all necessary and appropriate regulatory
approvals, licenses, registrations and authorizations from the applicable
Regulatory Authority to manufacture, use, store, import, export, transport,
promote, market and sell any Product in a country, and any renewals of the
foregoing.

                                       5
<PAGE>

                                                                    Confidential

      "Regulatory Authority" shall mean any governmental authority or agency
charged with issuing approvals, licenses, registrations or authorizations
necessary for the manufacture, use, storage, import, export, transport,
marketing, promotion or selling of any Product in a country.

      "Recall" shall have the meaning set forth in Section 4.3.

      "Special Transaction" shall mean, collectively, the following: (i) the
transfer by ICU to Hospira of all tangible assets the use of which is
exclusively or more than 50% devoted to the manufacture of Transferred Products,
Transferred Components, New Joint Products and New Hospira Competitive Products
under this Agreement, in exchange for a payment by Hospira to ICU of the net
book value (defined in accordance with GAAP) of such assets, (ii) the grant by
ICU to Hospira of a non-exclusive license on commercially reasonable terms to be
negotiated in good faith by the Parties of all rights to any intellectual
property rights owned solely by ICU that is necessary to manufacture and sell
New Joint Products; (iii) the transfer by ICU to Hospira, and the release by ICU
of all rights to all manufacturing processes, documentation, specifications,
know-how, intellectual property and Regulatory Approvals necessary for the
manufacture and sale of the Transferred Products, Transferred Components and New
Hospira Competitive Products; (iv) the provision by ICU to Hospira of a copy of
all manufacturing processes, documentation, specifications, know-how,
intellectual property and Regulatory Approvals to the New Joint Products; and
(v) the cooperation of the Parties with respect to all of the foregoing, and
with respect to any further transfer of items described above by Hospira to any
Third Party; provided that ICU shall not be required to grant licenses or
transfer the items described in clauses (iii) and (iv) above that relate to ICU
proprietary components or products, but shall sell such components or products
to Hospira on commercially reasonable terms.

      "Specifications" shall mean those product formulations, standards,
requirements and manufacturing, labeling, packaging and performance
specifications for the Products and Specified Components as determined by
Hospira and in effect at the time of manufacture of such Products and Specified
Components in accordance with Section 3.1.

      "Specified Components" shall mean those components of the Transferred
Products or Transferred Components that, before the Effective Date, were
manufactured at Hospira facilities other than the Facility and supplied to the
Facility, as more particularly described on Exhibit 1.1A.

      "Standard Products" shall mean Products that are not Custom Products.

      "Surgicare Products" shall mean those Transferred Products identified as
Surgicare Products on Exhibit 1.1C, as such Transferred Products may be improved
or modified from time to time through changes to the Specifications in
accordance with Section 3.1.

      "Term" shall have the meaning set forth in Section 13.1.

                                       6
<PAGE>

                                                                    Confidential

      "Third Party" shall mean any Person other than the Parties and their
Affiliates.

      "Third Party Rights" shall have the meaning set forth in Section 3.2(c).

      "Transfer Price Credit" shall have the meaning set forth in Section
2.7(b)(i)(D).

      "Transferred Components" shall mean those components that, before the
Effective Date, were manufactured at the Facility and supplied to other Hospira
facilities and Third Parties and are listed on Exhibit 1.1B, as such components
may be improved or modified from time to time through changes to the
Specifications in accordance with Section 3.1.

      "Transferred Products" shall mean those products that, before the
Effective Date, were manufactured at the Facility and are listed on Exhibit
1.1C, as such products may be improved or modified from time to time through
changes to the Specifications in accordance with Section 3.1, unless such
changes to the Specifications result in the creation of a New Joint Product, as
provided in the definition of New Joint Product.

      "United States" shall mean the United States of America and shall include
its territories and possessions, the District of Columbia and Puerto Rico.

      1.2 Definitions Relating to Pricing. Certain words and phrases used herein
and related to pricing have the meanings set forth in Exhibit 1.2.

                   ARTICLE 2 - PURCHASE AND SALE OF PRODUCTS

      2.1 Purchase and Sale of Products.

            (a) Transferred Products. During the Term, Hospira shall purchase
all of its requirements of the Transferred Products for sale in the United
States (provided that Hospira shall purchase all of its worldwide requirements
for Catheters) from ICU, and ICU shall manufacture and sell Transferred Products
exclusively to Hospira on a worldwide basis, in accordance with the terms
hereof. If Hospira plans to transfer the manufacture of products comparable to
the Transferred Products from its Ireland facility or Costa Rica facility to
Third Parties, Hospira shall provide ICU with notice and negotiate in good faith
with ICU for the manufacture by ICU of such products. In addition, if Hospira
plans to sell the Transferred Products (other than the Catheters) to its
customers outside the United States, Hospira shall provide ICU with notice and
negotiate in good faith with ICU for the manufacture by ICU of such products;
provided that if Hospira and ICU are unable to reach agreement within 90 days
after notice, Hospira may transfer the manufacture of such Transferred Products,
or such products comparable to Transferred Products, to Third Parties.

            (b) Transferred Components.

                  (i) For a period of five years after the Effective Date,
Hospira shall purchase all of its requirements of the Transferred Components
from ICU (but only to the extent that such Transferred Components are to be
incorporated into products, whether Transferred Products or not, that use

                                       7
<PAGE>

                                                                    Confidential

Transferred Components manufactured at the Facility as of the Effective Date),
and ICU shall manufacture and sell such Transferred Components exclusively to
Hospira, in accordance with the terms hereof; provided that ICU shall be able to
sell such Transferred Components to Third Parties if such Transferred Components
were sold to such Third Parties by Hospira as of the Effective Date. Nothing in
this Section 2.1(b) shall be deemed to prohibit Hospira from manufacturing, or
having manufactured by a Third Party, components that are the same as or similar
to the Transferred Components for use in products that do not use Transferred
Components manufactured at the Facility as of the Effective Date.

                  (ii) From and after the date that is five years after the
Effective Date, Hospira may manufacture, or have manufactured by a Third Party,
Transferred Components for incorporation into any product if ICU does not
provide transfer prices for such Transferred Components equal to or less than
Hospira can obtain by such self- or Third-Party manufacturing.

                  (iii) Notwithstanding the foregoing, with respect to those
Transferred Components that, as of the Effective Date, are purchased from Third
Parties by Hospira and shipped to other Hospira facilities, Hospira may, at its
option, elect to purchase such Transferred Components directly from a Third
Party, rather than through ICU; provided Hospira gives ICU commercially
reasonable notice of such election.

            (c) Other Products. During the Term, Hospira shall purchase from
ICU, and ICU shall manufacture and sell exclusively to Hospira, in accordance
with the terms hereof, (i) New Joint Products and (ii) any New ICU Competitive
Product or New Hospira Competitive Product that ICU has agreed in writing to
manufacture and sell to Hospira and Hospira has agreed in writing to purchase
from ICU, in accordance with Article 8.

Nothing contained in this Agreement shall be construed to obligate Hospira to
purchase any minimum quantity of any of the Products, except as provided in
Section 3.2(a) (Forecasting).

      2.2 Purchase Orders.

            (a) Purchase Orders. Hospira shall deliver purchase orders to ICU on
Hospira's then applicable purchase order form (each a "Purchase Order") at least
(i) 21 days prior to the delivery date specified therein if such Purchase Order
is for Custom Products unless any such Custom Product requires a component that
is not then manufactured or purchased by ICU, (ii) 30 days prior to the delivery
date specified therein if such Purchase Order is for Standard Products that have
been included in the binding forecast delivered to ICU pursuant to Section
3.2(a), and (iii) at least 45 days prior to the delivery date specified therein
if such Purchase Order is for Standard Products not included in the binding
forecast delivered to ICU pursuant to Section 3.2(a) or for Custom Products that
require a component not then manufactured or purchased by ICU. Each Purchase
Order shall include the following information: Product list number and
description, quantity, the applicable Transfer Price, required delivery
schedule, delivery location, and shipping instructions. ICU shall accept all
such Purchase Orders; provided, that ICU shall not be required to accept any
Purchase Order for quantities of Products to be delivered in any month to the
extent such quantities exceed the lesser of (A) 125% of the aggregate quantities
for all Products ordered by Hospira pursuant to Purchase Orders that ICU was

                                       8
<PAGE>

                                                                    Confidential

required to accept hereunder in the same month for the previous calendar year
and (B) 125% of the aggregate quantities for all Products forecast for such
month in the most recent binding forecast delivered to ICU pursuant to Section
3.2(a), but will use all commercially reasonable efforts to fill such orders for
quantities over 125%. If there are significant changes in the Product mix
reflected in Purchase Orders from the Product mix ordered for the same month for
the previous calendar year or reflected in the most recent binding forecast,
then the Parties will consider such significant changes when comparing the total
aggregate quantities and negotiate in good faith to determine the quantities for
which ICU will be required to accept Purchase Orders. With respect to the first
12 months of this Agreement, the foregoing reference to the aggregate quantities
for all Products purchased by Hospira in the same month for the previous
calendar year shall mean the quantities of Products manufactured by Hospira in
the same month for the previous calendar year. Purchase Orders shall be
non-cancelable, subject to Section 3.2(c) (Failure to Supply) below. Hospira
will issue Purchase Orders with respect to all of the WIP (as defined in the
Asset Purchase Agreement) with the Transfer Prices set in accordance with
Section 2.3(a).

            (b) Agreements Governing. All purchases of the Products by Hospira
from ICU during the Term shall be subject to the terms and conditions of this
Agreement, and any terms or conditions contained in a Purchase Order or
confirmation form which conflict with this Agreement shall be of no force and
effect unless the Parties specifically agree in writing to such terms and
conditions.

            (c) Custom Products. ICU shall make commercially reasonable efforts
to reduce the delivery time for Custom Products from the applicable delivery
time specified in Section 2.2(a) above if Hospira reasonably determines that
such a reduced delivery time is necessary to remain competitive in the Custom
Product market.

      2.3 Transferred Product and Transferred Component Pricing (Excluding
Surgicare Products).

            (a) The initial Transfer Price (along with the Cost Savings
Estimate) for each of the Transferred Products and Transferred Components (other
than Surgicare Products) sold by ICU to Hospira hereunder shall be as set forth
on Exhibit 2.3 and shall be the Transfer Price until December 31, 2005. On or
before September 1 of each Contract Year, ICU shall make a good faith estimate
of the Cost Savings it expects to achieve for each Transferred Product or
Transferred Component (other than Surgicare Products) during the subsequent
Contract Year (the "Cost Savings Estimate") and shall submit such estimate,
along with its estimate of the Fully Burdened Manufacturing Cost and the
resulting Transfer Price for such Products, determined in accordance with
Exhibit 2.3(A), to Hospira in writing for approval, which approval shall not be
unreasonably withheld. Notwithstanding the foregoing, the Parties will negotiate
in good faith to adjust the Transfer Prices prior to such annual change if it
becomes apparent that the Transfer Price does not, or will not, materially
reflect the agreement set forth in Exhibit 2.3(A) in order to minimize future
Quarterly Variances. Notwithstanding the foregoing, with respect to Products
that resulted from the WIP (as defined in the Asset Purchase Agreement)
purchased by ICU pursuant to the Asset Purchase Agreement and, on the Effective
Date, that had completed the manufacturing process and were either awaiting
sterilization or in sterilization or awaiting the final quality assurance
release, the Transfer Price shall be Hospira's 2005 standard cost as set forth
in Exhibit 2.3.

                                       9
<PAGE>

                                                                    Confidential

            (b) The Parties shall negotiate in good faith to develop, prior to
September 1 of Contract Year 2008 and each Contract Year thereafter, a method of
determining the Transfer Prices for Products for the following Contract Year
that eliminates the on-going calculation of Cost Savings and minimizes or
eliminates any Quarterly Variance or other reconciliation process, in any case
maintaining the general margin profile for each Party that results from the
agreement described in Exhibit 2.3(A).

      2.4 RESERVED

      2.5 Surgicare Product Pricing. The initial Transfer Price for each of the
Surgicare Products sold by ICU to Hospira hereunder shall be as set forth on
Exhibit 2.3 and shall be the Transfer Price until December 31, 2005. On or
before September 1 of each Contract Year, ICU shall determine the Transfer Price
it expects to charge Hospira for each Surgicare Product during the subsequent
Contract Year in accordance with Exhibit 2.5 and shall submit such estimate to
Hospira in writing for approval, which approval shall not be unreasonably
withheld.

      2.6 New Joint Product Pricing. The Transfer Price for each New Joint
Product sold by ICU to Hospira hereunder shall be as set forth in Exhibit 2.6.

      2.7 Payment.

            (a) Invoices. ICU shall invoice Hospira at the time of shipment for
all Products purchased by Hospira hereunder at the Transfer Price specified in
the applicable Purchase Order. Such invoices shall be paid in U.S. Dollars
within 30 days after the invoice date.

            (b) Reconciliation of Transfer Prices with Actual Costs.

                  (i) Calculation. ICU shall submit to Hospira within 10 days
      following the end of each quarter a good faith estimate of each of the
      calculations in clauses A, B, C and D below. ICU shall use commercially
      reasonable efforts to submit to Hospira as soon as possible following the
      end of each quarter, and in no event later than 25 days after the end of
      each quarter, its actual calculations of each of the following:

                  (A) For Transferred Products (excluding Surgicare Products)
                  and Transferred Components, the aggregate actual Cost Savings
                  minus the aggregate Cost Savings Estimate (or, if greater, the
                  applicable Guaranteed Cost Savings), in each case for all
                  Transferred Products (excluding Surgicare Products) and
                  Transferred Components sold by ICU to Hospira during such
                  quarter, multiplied by the applicable Cost Savings Percentage,
                  (the "Quarterly Variance");

                                       10
<PAGE>

                                                                    Confidential

                  (B) For Surgicare Products, the Transfer Price minus the Final
                  Surgicare Product Cost, for all Surgicare Products sold by ICU
                  to Hospira during such quarter (the "Quarterly Surgicare
                  Variance");

                  (C) For New Joint Products, the Transfer Price minus the Final
                  New Joint Product Cost, for all New Joint Products sold by ICU
                  to Hospira during such quarter (the "Quarterly New Joint
                  Product Variance"); and

                  (D) The number of direct labor hours used to produce Products
                  during such quarter. Hospira shall receive a credit (the
                  "Transfer Price Credit") for such quarter if such number is
                  equal to or greater than 208,750 hours in that quarter. The
                  amount of the Transfer Price Credit is set forth on Exhibit
                  2.7(b).

                  If the sum of the Quarterly Variance, Quarterly Surgicare
      Variance, Quarterly New Joint Product Variance and Transfer Price Credit,
      if any, is less than zero, then such sum shall be the "Shortfall Amount".
      If such sum is greater than zero, then such sum shall be the "Overpayment
      Amount". Hospira shall have 30 days after receipt of such calculations to
      (x) review and approve such calculations or (y) elect to have an audit of
      the applicable financial records of ICU performed by Hospira, or its
      representative, during normal business hours and upon at least five
      Business Days' notice to ICU. In addition, Hospira shall also have annual
      Audit Rights with respect to such calculations. ICU shall pay the cost (A)
      of any quarterly audit performed by Hospira if the Parties agree that the
      results of such audit establish that the Shortfall Amount or Overpayment
      Amount were miscalculated in ICU's favor by more than $25,000 or (B) of
      any audit conducted pursuant to Hospira's Audit Rights if the results of
      any such audit establish that the Shortfall Amount or Overpayment Amount
      was miscalculated in ICU's favor by more than $100,000. All individuals
      conducting any audits shall sign a non-disclosure agreement with ICU on
      terms at least as stringent as those contained in this Agreement.

                  (ii) Payment. Hospira shall pay ICU the Shortfall Amount, if
      any, within 30 days of the date of Hospira's approval of ICU's
      calculations or completion of the audit, as applicable, in accordance with
      Subsection (i) above. ICU shall reimburse Hospira the Overpayment Amount,
      if any, within 30 days of the date of Hospira's approval of its
      calculations or completion of the audit, as applicable, in accordance with
      Subsection (i) above.

      2.8 Raw Materials Reimbursement.

            (a) ICU shall use commercially reasonable efforts to use the Raw
Materials (as defined in the Asset Purchase Agreement) transferred to ICU
pursuant to the Asset Purchase Agreement in the manufacturing operations of ICU.

            (b) If at the date that is 18 months after the Effective Date, ICU
has not sold or used any portion of the Raw Materials in its manufacturing
operations, then ICU shall receive a credit on the next quarterly reconciliation
pursuant to Section 2.7 equal to the gross value of the unused and unsold
portion of Raw Materials less the amount of the reserves for Raw Materials on
Hospira's books on the Effective Date, up to a maximum credit in the amount of
10 percent of the gross value as of the Effective Date of such Raw Materials.

                                       11
<PAGE>

                                                                    Confidential

            (c) If ICU uses or sells any portion of such Raw Materials at any
time after receiving a credit from Hospira pursuant to this Section 2.8, ICU
shall return to Hospira the portion of such credit attributable to the Raw
Materials used or sold by ICU.

            (d) Hospira shall have Audit Rights with respect to any calculations
pursuant to this Section 2.8 if the Parties are unable to resolve any dispute
through good faith discussions within 30 days of Hospira's dispute of such
calculations. The cost of any audit under this Section 2.8(d) shall be paid by
Hospira or ICU as determined in accordance with Section 2.7(b)(i).

                      ARTICLE 3 - MANUFACTURE OF PRODUCTS

      3.1 Manufacture of Products.

            (a) Specification Changes.

                  (i) Initiated by Hospira. Hospira may amend the Specifications
            from time to time with the prior written consent of ICU, which
            consent shall not be unreasonably withheld, and any resulting
            changes to the Fully Burdened Manufacturing Cost for a Product will
            be reflected in the applicable Transfer Price in accordance with the
            terms of Article 2. If any amendment to the Specifications requires
            Regulatory Approval, ICU and Hospira, as the case may be, shall make
            commercially reasonable efforts to obtain such Regulatory Approval
            as quickly as possible as required by Section 4.1 and ICU shall not
            implement such change until such Regulatory Approval has been
            received.

                  (ii) Initiated by ICU. ICU may amend the Specifications from
            time to time with the prior written consent of Hospira, which
            consent shall not be unreasonably withheld and any resulting changes
            to the Fully Burdened Manufacturing Cost for a Product will be
            reflected in the applicable Transfer Price in accordance with the
            terms of Article 2. If any change to the Specifications requires
            Regulatory Approval, ICU and Hospira, as the case may be, shall make
            commercially reasonable efforts to obtain such Regulatory Approval
            as quickly as possible as required by Section 4.1 and ICU shall not
            implement such change until such Regulatory Approval has been
            received.

                  (iii) Cost Impact. Promptly following a request by Hospira,
            ICU shall provide Hospira with a good faith estimate of the impact
            on the Fully Burdened Manufacturing Cost of any amendments to the
            Specifications proposed pursuant to this Section 3.1(a).

            (b) Manufacturing Changes.

                                       12
<PAGE>

                                                                    Confidential

                  (i) ICU shall notify Hospira in writing prior to the
            implementation of any changes in its manufacturing process for a
            Product that affect the fit, form or function of such Product
            ("Manufacturing Changes") and shall provide Hospira with a good
            faith estimate of the impact of such Manufacturing Changes on the
            Fully Burdened Manufacturing Cost. Such notice shall include
            Manufacturing Changes that affect the Specifications, written
            quality plans or procedures for production, manufacturing
            procedures, component parts, raw materials, vendors or batch sizes.

                  (ii) Upon Hospira's request, ICU shall provide to Hospira
            representative samples of Products manufactured using any
            Manufacturing Changes in sufficient quantities for Hospira to
            evaluate such Manufacturing Changes. Upon such notice of any such
            Manufacturing Changes and after receipt of such representative
            samples (if requested), Hospira shall use commercially reasonable
            efforts to evaluate and notify ICU of its approval (which shall not
            be unreasonably withheld) or disapproval of such Manufacturing
            Changes within 30 days after the date of notice, but in any event
            within 60 days after the date of notice. If Hospira does not notify
            ICU of its disapproval of such Manufacturing Changes within such
            period, then such Manufacturing Changes shall be deemed to be
            approved by Hospira, and ICU shall notify Hospira when it has
            implemented such Manufacturing Changes.

                  (iii) In the event any Manufacturing Change has an impact on
            any Regulatory Approval, the responsibilities and costs for any
            necessary amendments, notifications or resubmissions (as determined
            by the responsible Party) shall be allocated as provided in Section
            4.1. Changes to the Fully Burdened Manufacturing Cost caused by a
            Manufacturing Change will be reflected in the applicable Transfer
            Price in accordance with the terms of Article 2. If any
            Manufacturing Change requires Regulatory Approval, ICU and Hospira,
            as the case may be, shall use commercially reasonable efforts to
            obtain such Regulatory Approval as quickly as possible as required
            by Section 4.1 and ICU shall not implement such change until such
            Regulatory Approval has been received.

            (c) Manufacturing Site. ICU shall initially manufacture the Products
at the Facility. If ICU plans to move any manufacturing of Products to a
location other than the Facility, ICU shall use commercially reasonable efforts
to notify Hospira at least 60 days (but in any event not less than 30 days) in
advance of such move and allow Hospira to inspect such new manufacturing
facilities to ensure compliance of facilities, equipment, and procedures with
applicable FDA regulations and cGMPs. ICU shall not manufacture Products at the
new facility until such time as Hospira has completed its inspection confirming
compliance. ICU shall use commercially reasonable efforts to ensure a smooth
transition to a new manufacturing facility and to avoid delays in any such
transition. Hospira shall use commercially reasonable efforts to complete its
inspections on a timely basis to avoid delays in any such transition. In the
event a manufacturing site change has an impact on any Regulatory Approval, ICU
shall reimburse Hospira for the costs of any Regulatory Approval amendment,
notification or resubmission deemed necessary by Hospira in its sole discretion
as a result of such manufacturing site change and the manufacture of the
Products to the new manufacturing site shall not begin until all Regulatory
Approvals have been obtained.

                                       13
<PAGE>

                                                                    Confidential

            (d) Cost Reductions. ICU shall use all commercially reasonable
efforts to continuously reduce its Fully Burdened Manufacturing Cost for the
Products.

      3.2 Inventory and Supply Matters.

            (a) Forecasting. Hospira shall provide ICU with a rolling 12 month
forecast of its monthly requirements for the Products prior to the first day of
each calendar month during the Term, with the first three months of each such
forecast constituting a binding commitment by Hospira to purchase such
quantities. On a monthly basis, Hospira shall issue Purchase Orders in
accordance with Section 2.2(a) for the delivery during each month of the
quantities of Products as to which the then-current forecast is binding. The
last nine months of the forecast will not be binding on either Party and will be
used only for planning purposes.

            (b) Capacity. ICU shall maintain sufficient manufacturing capacity
and means to produce and timely deliver Hospira's forecasted requirements of the
Products during the Term in accordance with the terms of this Agreement, to the
extent that quarterly growth in the aggregate quantity of all Products forecast
by Hospira is not greater than 25% of the aggregate quantity of all Products
purchased by Hospira in the same calendar quarter for the previous calendar
year. With respect to the first 12 months of this Agreement, the foregoing
reference to the aggregate quantities for all Products purchased by Hospira
shall mean the quantities of Products manufactured by Hospira in the same
calendar quarter for the previous calendar year. Hospira shall have the right to
review ICU's manufacturing capacity throughout the Term and, at Hospira's
request, ICU shall provide to Hospira evidence of ICU's manufacturing capacity.

            (c) Failure to Supply. If ICU fails to deliver, or anticipates that
it will be unable to deliver, Products ordered pursuant to the terms of this
Agreement for 60 or more consecutive days past any Delivery Date, ICU will
promptly notify Hospira. Hospira shall have the right to (i) agree to a revised
delivery date, (ii) cancel some or all existing Purchase Orders for such
Products without penalty, (iii) transfer the manufacture of such Products to
itself or a Third Party, or (iv) to the extent such failure to supply is a
material breach, terminate this Agreement in accordance with Section 13.3. ICU
shall not be deemed to have failed to deliver under the preceding sentence if it
is unable to manufacture Products ordered by Hospira as a direct result of
Hospira's failure to supply ICU with Specified Components under Section 5.2
hereof or as a direct result of Hospira's breach of its obligations under
Sections 3.1(a), (b) or (c). If Hospira elects option (iii), ICU shall, if so
requested by Hospira, (A) transfer and/or license to Hospira, as applicable, all
know-how, technology, trade secrets and patent rights necessary to manufacture
such Products (other than with respect to any component of such Product that can
be timely supplied by ICU), thereby enabling Hospira or its designee to
manufacture such Products, (B) reasonably assist Hospira or its designee in the
transfer and the start-up of manufacturing operations for such Products and make
all necessary plans, formulations and manufacturing processes, procedures, test
methods, specialized test equipment, and other items available to Hospira or its

                                       14
<PAGE>

                                                                    Confidential

designee, (C) grant Hospira or its designee access to ICU's regulatory files
relating to such Products, (D) transfer all Regulatory Approvals to Hospira
necessary to manufacture, market and sell such Products, and (E) supply such
other technical or regulatory assistance as is reasonably requested by Hospira
or its designee. ICU hereby grants to Hospira, without the necessity of any
further documentation, a non-exclusive, royalty free, irrevocable, worldwide
right and license to ICU's know-how, technology, trade secrets and patent rights
to make, have made, use and sell such Products. To the extent any know-how,
technology, trade secrets or patent rights are owned, controlled or licensed by
a Third Party ("Third Party Rights"), and are required to implement Hospira's
right to manufacture or have manufactured such Products, ICU shall use its best
efforts to obtain a license to all such Third Party Rights to allow Hospira or
its designee to use such Third Party Rights for the production of Products.

            (d) Certain Temporarily Unavailable Products. Hospira may enter into
long-term contracts with its customers for the sale of products ("Customer
Supply Agreements"). These Customer Supply Agreements may include a provision
that requires Hospira to pay any incremental costs incurred by a customer in the
event the customer must purchase the products covered under the Customer Supply
Agreement from another vendor due to a backorder situation with Hospira ("Cover
Costs"). In the event that Hospira is unable to supply a product to its
customers as a direct result of ICU's inability or unwillingness to supply
Products under Purchase Orders placed by Hospira and accepted by ICU in
accordance with Section 2.2(a), ICU agrees that it shall be responsible for and
shall reimburse Hospira for any such Cover Costs. ICU shall not be deemed to
have been unable to supply under the preceding sentence if it is unable to
manufacture Products ordered by Hospira as a direct result of Hospira's failure
to supply ICU with Specified Components under Section 5.2 hereof or as a direct
result of Hospira's breach of its obligations under Sections 3.1(a), (b) or (c).

            (e) Supply Resumption. If Hospira's manufacturing rights under
Section 3.2(c) above become effective because of ICU's inability to supply
Products and provided that Hospira has not elected to terminate this Agreement
pursuant to Section 13.3, and ICU is thereafter, during the Term, able to
demonstrate to Hospira's reasonable satisfaction that ICU is capable of
re-establishing and maintaining a satisfactory supply of such Products, then
Hospira shall transfer back to ICU all of the items, if any, previously
transferred by ICU to Hospira pursuant to Section 3.2(c) and resume purchasing
such Products from ICU for the remainder of the Term within 90 days after ICU
satisfactorily demonstrates its ability to meet Hospira's forecasts and ICU
reimburses Hospira for all incremental costs incurred by Hospira as a result of
Hospira manufacturing Products or having a Third Party manufacture Products
pursuant to Section 3.2(c) above. Notwithstanding the foregoing, Hospira shall
still be permitted to fulfill any contractual purchase commitments entered into
by Hospira with the Third Party manufacturer.

      3.3 Product Delivery.

            (a) Delivery Terms. Unless otherwise directed by Hospira, ICU shall
ship Products ordered by Hospira, FCA (Incoterms 2000) ICU's manufacturing
facility, in accordance with the quantities, delivery dates, and delivery and
shipping instructions specified in the applicable Purchase Order; provided that
if ICU moves manufacturing to a location other than the Facility or ICU's San

                                       15
<PAGE>

                                                                    Confidential

Clemente, California or Ensenada, Mexico facilities, any incremental increase in
shipping costs from such new location shall be shared equally by ICU and Hospira
and the Parties shall negotiate in good faith to implement procedures to
accomplish such cost sharing. If the carrier noted on the Purchase Order is not
available, or if the Purchase Order does not designate a carrier, then ICU shall
contact Hospira for instructions regarding the mode of shipment. ICU shall
deposit the Products with the designated carrier within the shipping periods
specified, and ICU shall not be liable for late delivery if so accomplished.
Title and risk of loss shall pass to Hospira upon delivery to the designated
carrier for shipment.

            (b) Delays. If ICU is unable to deliver the Products on or prior to
the applicable Delivery Date, ICU shall notify Hospira as soon as possible. If
Hospira incurs actual costs as a result of ICU's inability to deliver, other
than costs related to its exercise of rights under Section 3.2(c) (iii) or (iv),
ICU shall reimburse Hospira for such actual costs upon presentation of such
costs to ICU. ICU shall have Audit Rights with respect to such costs. The
Parties acknowledge that any notice of delay or reimbursement of Hospira's costs
under this Section will not affect Hospira's remedies for breach hereunder,
including those set forth in Section 3.2(c) (Failure to Supply). ICU shall not
be deemed to have been unable to deliver under this Section 3.3(b) if it is
unable to manufacture Products ordered by Hospira as a direct result of
Hospira's failure to supply ICU with Specified Components under Section 5.2
hereof or as a direct result of Hospira's breach of its obligations under
Sections 3.1(a), (b) or (c).

            (c) Certificates. ICU shall deliver to Hospira, in a form acceptable
to Hospira, for each shipment of Products one or more (i) certificates of
compliance indicating that representative samples of each lot of such Products
have been tested and including identities of the items tested, applicable
Specifications and test results, signed by a representative of the ICU quality
unit; and (ii) certificates of manufacturing compliance certifying that the
Products were manufactured in compliance with the applicable Specifications and
cGMPs, signed by a representative of the ICU quality unit. Hospira is entitled
to rely on such certificates at the time of delivery to Hospira. Such
certificates are required only for Products shipped directly to Hospira. For
Custom Products shipped directly to a customer of Hospira by ICU, ICU shall
maintain appropriate quality records, as reasonably requested by Hospira, which
may be reviewed by Hospira upon request.

            (d) Storage. Following delivery to Hospira, Hospira shall be
responsible for properly storing the Products in accordance with the
Specifications in facilities selected by Hospira.

            (e) Taxes. Hospira shall pay all sales and similar taxes payable
with respect to the sale and purchase of Products sold by Hospira, but not taxes
based on ICU's income or any importation duties.

      3.4 Shelf Life. At the time of shipment by ICU under this Agreement, all
Products shall have a remaining shelf life greater than the approved shelf life
for such Product less two months.

                                       16
<PAGE>

                                                                    Confidential

      3.5 Product Defects and Returns.

            (a) Inspection. Except for latent defects, Hospira or its customers,
as applicable, shall have a period of 30 days from the date of delivery to
notify ICU that a shipment of Products is damaged or does not contain the
correct quantities of Products. Hospira shall have no obligation to test
Products to confirm compliance with the Specifications and shall be entitled to
rely upon the certificate provided by ICU pursuant to Section 3.3(c) above.

            (b) Returns. Hospira shall have the right, with prior written notice
to ICU, to return any Product, or to have a customer return any Product, that is
damaged or otherwise does not conform to the Specifications. Prior to making any
such return, Hospira, or the customer, as the case may be, shall request a
return goods authorization from ICU and ICU shall promptly issue such return
goods authorization. ICU shall either credit Hospira's account or provide
non-defective replacement Products at no cost to Hospira. Should ICU determine
after investigation that any damage or non-conformity with the Specifications is
attributable to any breach of Hospira's obligations, including faulty
transportation or storage of the Product, then Hospira shall reimburse ICU for
the Transfer Price of such Products, transportation, storage and disposal.

            (c) Disputes. If a dispute arises as to whether a Product conforms
to the Specifications and the Parties are unable to resolve the dispute, the
matter shall be referred to an independent Third Party testing laboratory agreed
to by the Parties. The testing laboratory shall test the Product in question for
conformance with the Specifications and shall provide the results of its
analysis to ICU and Hospira. The decision of the testing laboratory regarding
conformance with the Specifications shall be final and binding on the Parties.
The cost of the testing laboratory shall be paid by the Party found to be in
error.

      3.6 Representations, Warranties and Covenants.

            (a) Adulteration and Misbranding. ICU represents, warrants and
covenants to Hospira (i) that Products delivered to Hospira pursuant to this
Agreement shall, at the time of delivery, not be adulterated or misbranded
within the meaning of the Act or within the meaning of any Laws in which the
definitions of adulteration and misbranding are substantially the same as those
contained in the Act, as the Act and such Laws are constituted and effective at
the time of delivery, (ii) that ICU shall not cause any act or omission in
relation to the Products that renders the Products adulterated or misbranded,
and (iii) that no Product will be an article which may not under the provisions
of Sections 404 and 505 of the Act be introduced into interstate commerce.

            (b) Compliance. ICU represents, warrants and covenants to Hospira
that Products ICU delivers to Hospira pursuant to this Agreement shall be free
from defects in material and workmanship and shall be manufactured (i) in
accordance with and in conformity with the Specifications, and (ii) in
compliance with all applicable Laws. ICU shall be responsible for all product
liability and quality assurance issues arising from any failure to comply with
Specifications and/or such Laws, provided, however, that ICU shall in no event
be responsible for failure of the Products to conform with Specifications and/or
such Laws if such failure is caused by the inappropriate storage, transportation
or distribution of the Products by Hospira for which Hospira alone shall be
responsible.

                                       17
<PAGE>

                                                                    Confidential

            (c) Quality Control. ICU and Hospira will negotiate in good faith
and shall enter into a separate quality agreement within 60 days of the
Effective Date in format mutually agreed upon by the Parties and suitable to
meet Regulatory Authority requirements documenting communication, Products
descriptions, Specifications, manufacturing standards and measures to ensure
compliance with applicable regulations relating to the production, storage,
transportation, and release of Products. In the event of a conflict between this
Agreement and such quality agreement or agreements, the terms of this Agreement
shall control.

            (d) Facilities. Except to the extent directly caused by Hospira's
breach of its representations and warranties under Section 4.16 of the Asset
Purchase Agreement, ICU represents, warrants and covenants that any
manufacturing facilities and processes utilized for the manufacture of the
Products will comply with applicable government regulations, including
applicable cGMPs.

            (e) Product Safety. ICU represents, warrants and covenants that
Products supplied by ICU to Hospira under this Agreement shall comply with all
product safety regulations regarding hazardous classification, appropriate
labeling requirements and requisite Material Safety Data Sheets ("MSDSs"),
including OSHA (United States Occupational Safety Health Administration); DOT
(United States Department of Transportation); EPA (United States Environmental
Protection Agency); FDA; EC (European Community); IATA/ICAO (International Air
Transportation Association/International Civil Aviation Organization); Prop-65
(California proposition regarding notification to individuals about hazardous
substances in products); and WHMIS (Workplace Hazardous Material Information
System), in any country in which Products may be distributed by Hospira. ICU
shall provide to Hospira upon Hospira's request copies of MSDSs and any other
information and documentation related to product safety, including but not
limited to physical, chemical, and biological characteristics of the Products.
ICU shall implement a procedure that complies to the above regulatory agency
requirements. Notwithstanding anything in this provision to the contrary, ICU
shall be solely responsible for all such safety matters related to the Products.

            (f) No Other Representations or Warranties. EXCEPT AS EXPRESSLY SET
FORTH IN THIS AGREEMENT, ICU MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR
IMPLIED, WITH RESPECT TO THE PRODUCTS. ALL OTHER WARRANTIES, EXPRESS OR IMPLIED,
INCLUDING THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR
PURPOSE, ARE HEREBY DISCLAIMED BY ICU.

      3.7 Access to Manufacturing Documents. Hospira shall provide ICU with
copies of, or reasonable access to, all records and documents reasonably
necessary to manufacture the Products, including historical supplier lists,
purchasing and shipping records, artwork, product development reports,
production flowcharts and regulatory affairs communications including inspection
reports.

                ARTICLE 4 - REGULATORY MATTERS AND COMMUNICATION

                                       18
<PAGE>

                                                                    Confidential

      4.1 Regulatory Approvals.

            (a) United States. As of the Effective Date, Hospira has obtained
all Regulatory Approvals required to manufacture and market the Transferred
Products and Transferred Components that are sold in the United States as of the
Effective Date. Hospira hereby transfers to ICU all domestic Regulatory
Approvals owned by Hospira as set forth in Exhibit 4.1(a) and the Parties shall
cooperate with each other to effect such transfers. ICU, at its sole cost and
expense, shall (i) maintain and keep current during the Term all such Regulatory
Approvals required in the United States to manufacture and market the
Transferred Products and Transferred Components and (ii) obtain, maintain and
keep current all Regulatory Approvals required in the United States to
manufacture and market all Products, other than Transferred Products and
Transferred Components. ICU shall keep Hospira apprised of the status of such
Regulatory Approvals as requested by Hospira.

            (b) Foreign Countries. Hospira, at its sole cost and expense, shall
use reasonable commercial efforts to obtain, maintain and keep current all
additional Regulatory Approvals, if any, for the Products in all countries
outside the United States in which Hospira decides to market and sell any
Products. ICU shall, at its sole cost and expense, assist Hospira in preparing
the regulatory submissions, including generating any data required for such
submissions, and shall consult with and advise Hospira in responding to
questions from any Regulatory Authority regarding any such submissions for any
Products. Hospira shall be the sole owner of any submission to a Regulatory
Authority filed by it pursuant to this Agreement.

      4.2 Communications With United States and Foreign Regulatory Authorities.

            (a) United States. ICU shall be responsible for all communications
with the FDA related to the Products. Neither Party shall initiate or respond to
communications with the FDA or any other Regulatory Authority in the United
States without previously consulting with the other Party. Each Party shall
promptly, and in any event within two Business Days, communicate to the other
Party the substance of all material matters communicated between such Party and
any Regulatory Authority in the United States that relate to the Products.

            (b) Foreign. Hospira shall be responsible for all communications
with foreign Regulatory Authorities related to the registrations, CE marking,
manufacture, importation, marketing, and sale of the Products. Hospira shall
promptly, and in any event within two Business Days, communicate to ICU the
substance of all material matters communicated between Hospira and any foreign
Regulatory Authority that relate to the Products.

      4.3 Product Recalls. Should any Product's defect or any Regulatory
Authority action attributable to a Product's defect require (a) the recall,
destruction or withholding from market of any Product (a "Recall") or (b)
institution of a field correction of any Product (a "Field Correction"), Hospira
and ICU must notify each other within two Business Days of becoming aware of
such defect or governmental action. If a Recall or Field Correction is deemed
necessary by any Regulatory Authority, by ICU in the United States, or by
Hospira outside the United States, then ICU and Hospira shall provide the
appropriate level of support for the Recall or Field Correction as shown in
Exhibit 4.3. ICU will consider in good faith Hospira's suggestions and Hospira
and ICU will work together to develop the strategy for carrying out the Recall
or Field Correction. Hospira and ICU will each use commercially reasonable
efforts to support such strategy. Hospira shall be responsible for the costs and

                                       19
<PAGE>

                                                                    Confidential

expenses of such Recall or Field Correction to the extent such Recall or Field
Correction is attributable to any negligent acts or omissions or willful
misconduct by Hospira, its Affiliates or their respective officers, directors,
employees and agents, or Hospira's breach of this Agreement, and ICU shall be
responsible for the costs and expenses of such Recall or Field Correction in all
other circumstances. ICU shall be responsible as manufacturer for the
preparation of any required reports or information that under applicable Laws
must be submitted to a Regulatory Authority with respect to any Product
complaints, adverse events, Product withdrawals, Recalls or Field Corrections or
other corrective actions. Hospira will be responsible for submitting such
reports to Regulatory Authorities outside the United States. Any information of
any nature disclosed by one Party to the other in connection with such Recall or
Field Correction shall be considered Confidential Information of the disclosing
Party.

      4.4 Site Inspections. Upon at least 10 Business Days' prior notice, unless
a shorter period is needed due to the circumstances, ICU shall, from time to
time during the Term, allow representatives of Hospira to inspect all facilities
utilized by ICU in the manufacture, testing, packaging or shipment of the
Products for the purpose of verifying compliance with ICU's obligations under
this Agreement. During such inspections (and at other reasonable times), ICU
shall provide reasonable access to its regulatory, manufacturing and quality
control documentation and shall cooperate with such representatives in every
reasonable manner. Hospira may request that ICU complete and return assessment
forms or other documentation intended to allow Hospira to assess ICU's
performance of its obligations under this Agreement. On any inspection or audit
by Hospira or by any governmental agency which results in required corrective
actions, ICU shall have such time as is provided by such agency or as is
commercially reasonable, as the case may be, to take all needed steps to
implement the corrective actions identified in the aforementioned audits or
inspections. Hospira shall furnish ICU a written report of any such inspection
or audit within 30 days of the completion thereof. Nothing in this provision is
to be construed so as to place a duty on Hospira to make any such inspection or
audit or to determine whether or not ICU is in compliance with its obligations
hereunder or applicable Laws. No determination by Hospira that ICU is or is not
in compliance shall be construed as relieving ICU from its duty to determine if
it is in such compliance and to comply with such Laws.

      4.5 Regulatory Compliance. ICU shall comply with any applicable Laws that
require ICU to (a) allow representatives of the FDA or any Regulatory Authority
to inspect all facilities utilized by ICU in the manufacture, testing,
packaging, storage and shipment of the Products, or (b) respond to requests for
information from the FDA or any other Regulatory Authority. In addition, ICU
shall cooperate with such representatives in every reasonable manner. ICU shall
notify Hospira immediately whenever ICU receives notice of a pending inspection
of any facility utilized by ICU in the manufacture, testing, packaging, storage
or shipment of the Products by any Regulatory Authority. Hospira, at its
expense, shall provide Hospira quality assurance or regulatory affairs personnel
to consult with ICU in connection with any FDA audit during 39 the six month
period following the Effective Date involving the Facility or Products
manufactured in the Facility; provided, however, that such assistance shall not
relieve ICU of any responsibility or liability set forth in this Agreement.
Thereafter, Hospira at its option and expense, shall provide Hospira quality
assurance or regulatory affairs personnel to consult with ICU in connection with

                                       20
<PAGE>

                                                                    Confidential

any FDA audit involving the Facility or Products manufactured in the Facility,
provided, however, that such assistance shall not relieve ICU of any
responsibility or liability set forth in this Agreement. ICU shall also provide
Hospira with a copy of any FDA form 483 notices (or comparable notice from any
other Regulatory Authority) of adverse findings, regulatory letters or similar
writings it receives from any Regulatory Authority setting forth adverse
findings or non-compliance with applicable Laws relating to any Product within
two Business Days of its own receipt and a copy of any summary thereof prepared
by ICU or its agents. If a foreign Regulatory Authority inspects ICU's
facilities, Hospira may, at its option, have a representative at ICU's facility
during the inspection. Hospira shall be responsible for responding to the
foreign Regulatory Authority and shall consult with ICU prior to making any
written response. Hospira shall provide ICU with a copy of Hospira's written
response to such Regulatory Authority within two Business Days of its submission
thereof. ICU shall treat such written responses as Confidential Information.

      4.6 Product Complaints. Hospira shall notify ICU in writing as promptly as
possible, but at least within two Business Days, of any customer complaints that
relate to the Products. ICU shall notify Hospira in writing as promptly as
possible, but at least within two Business Days, of any customer complaints that
relate to the Products. ICU shall investigate all Product complaints or adverse
experiences and determine the cause of any alleged Product manufacturing defect.
ICU shall conduct the necessary investigations to Hospira's reasonable
satisfaction and shall use commercially reasonable efforts to report the
findings of the investigations as soon as reasonably practicable, but in any
event within 30 days (except within 15 days for investigations related to Japan)
from receipt of notice of the complaint from Hospira. Hospira shall be
responsible for customer response communications and shall provide a copy of
such communications to ICU. ICU shall be responsible for all medical adverse
event reports required by Regulatory Authorities and shall provide Hospira with
a copy of such reports within two Business Days of submission to a Regulatory
Authority; provided that in countries where Hospira is the product license
holder and the product license holder is required to report adverse events, ICU
shall provide the applicable adverse event reports and Product complaint
information to Hospira for submission by Hospira to the Regulatory Authority.

      4.7 Labeling. Hospira shall provide ICU with the form and content for all
labeling for the Products from time to time during the Term. ICU agrees to
manufacture Products with labeling needed for each country of sale as requested
by Hospira, the cost of which is included in the Transfer Price. All Products
shall be labeled prominently with the Hospira name, and may or, if required by
applicable Laws shall, identify ICU less prominently as the manufacturer. ICU
shall mark each saleable Product unit with the applicable Hospira list number,
as specified by Hospira, the applicable ICU lot number and, as specified by
Hospira and reasonably agreed to by ICU, the applicable bar code. Hospira shall
supply ICU with Product list numbers, lot number suffixes and lot number blocks
in a timely manner.

      ARTICLE 5 - MANUFACTURE AND SUPPLY OF SPECIFIED COMPONENTS

      5.1 Manufacture. For five years after the Effective Date, Hospira shall
manufacture and supply to ICU all of ICU's requirements of the Specified
Components, upon commercially reasonable notice from ICU, at the initial prices
set forth in Exhibit 1.1A. Starting on January 1, 2006, the pricing for

                                       21
<PAGE>

                                                                    Confidential

Specified Components shall be equal to Hospira's Fully Burdened Manufacturing
Cost plus 15%. Hospira shall provide ICU with 90 days' notice of any price
increases and ICU shall have the option to accept the price increases or provide
90 days' notice that it shall cease ordering such Specified Components.
Notwithstanding the foregoing, ICU shall have no obligation to purchase
Specified Components from Hospira after the first anniversary of the Effective
Date, provided that ICU gives Hospira at least six months written notice of
ICU's intent to cease purchasing the Specified Components from Hospira.

      5.2 Purchase Orders and Forecasts. ICU shall deliver purchase orders on
its then applicable purchase order form to Hospira at least 60 days prior to the
delivery date specified therein. Each such purchase order shall include the
following information: Specified Component list number and description,
quantity, price, requested delivery schedule, delivery location, and shipping
instructions. Hospira shall ship Specified Components ordered by ICU, FCA
(Incoterms 2000) Hospira's manufacturing facility. Other purchase order terms
shall be negotiated in good faith by the Parties. ICU shall provide Hospira with
a rolling 12 month forecast of its monthly requirements for the Specified
Components prior to the first day of each calendar month during the Term, with
the first three months of each such forecast constituting a binding commitment
by ICU to purchase such quantities. On a monthly basis, ICU shall issue purchase
orders in accordance with this Section 5.2 for the delivery during each month of
the quantities of Specified Components as to which the then-current forecast is
binding. The last nine months of the forecast will not be binding on either
Party and will be used only for planning purposes.

      5.3 Permitted Uses. ICU agrees that it shall not use Specified Components
supplied by Hospira for any use other than Products sold to Hospira under this
Agreement.

        ARTICLE 6 - MARKETING, SELLING AND CUSTOMER SERVICE FOR PRODUCTS

      6.1 Hospira's Responsibilities. Hospira shall have the following rights
and responsibilities related to the marketing and sale of all Products:

            (a) Sales and Marketing. Subject to Hospira's right to request and
receive technical and product sales support pursuant to Section 6.2(a), Hospira
shall have the exclusive right and the sole responsibility for lead generation,
sales, marketing, promotion and product positioning activities (including the
selection of distribution, co-promotion and/or co-marketing partners if Hospira
so elects). In the United States, for the first five Contract Years Hospira
shall devote sales, marketing, and promotion personnel in connection with its
responsibilities under this Agreement as provided on Exhibit 6.1(a). Thereafter,
Hospira shall incur commercially reasonable sales and marketing expenses in
connection with its responsibilities under this Section 6.1(a). ICU shall have
Audit Rights to confirm compliance with this Section 6.1(a).

            (b) Contracting. Hospira shall have the exclusive right and sole
responsibility to determine the terms of sale and to enter into all sales
contracts.

                                       22
<PAGE>

                                                                    Confidential

            (c) Pricing. Hospira shall have the exclusive right and sole
responsibility for establishing all prices and pricing strategies.

            (d) Billing and Collection. Hospira shall have sole responsibility
for billing customers and collecting payment.

            (e) Product Returns. Subject to Section 3.5 (Product Defects and
Returns), Hospira shall have sole responsibility for handling all Product
returns by customers.

            (f) Inventory. Hospira shall maintain a commercially reasonable
supply of Standard Products in inventory.

            (g) Brand Name. Hospira shall determine the trade name and/or brand
name under which the Products shall be marketed, whether individually or as a
component of another Hospira product, and shall be the sole owner of any such
brand or trade name.

            (h) Customer Service. Hospira shall be responsible for all customer
service issues (including medical inquiries), except as provided in Section
6.2(b) below.

            (i) Compliance with Laws. Hospira shall conduct its sales and
marketing activities hereunder in compliance with all applicable Laws.

      6.2 ICU's Responsibilities.

            (a) Sales Support. In the United States, ICU shall devote
field-based technical and product sales support specialists to assist Hospira
with its duties under Section 6.1 for the first five Contract Years as provided
on Exhibit 6.1(a). Thereafter, ICU shall provide a commercially reasonable
number of field-based technical and product sales support specialists to assist
Hospira with its duties under Section 6.1; provided that ICU shall not be
required to provide technical and product sales support specialists with respect
to Surgicare Products. Hospira shall have Audit Rights to confirm compliance
with this Section 6.2(a).

            (b) Customer Service. ICU shall be responsible for customer service
issues related to questions about the Specifications and technical support
(non-medical) for the Products.

            (c) Compliance with Laws. ICU shall conduct its activities hereunder
in compliance with all applicable Laws.

                     ARTICLE 7 - JOINT PRODUCT DEVELOPMENT

      7.1 Planning and Spending.

            (a) Subject to Section 7.1(b) below, the Parties shall agree from
time to time in writing during the Term to pursue certain product development
priorities with the goal of developing New Joint Products and improvements to
the Products. The initial product development priorities agreed to by the
Parties are set forth on Exhibit 7.1. Hospira and ICU shall agree in a timely
manner on a specific product definition for each development priority. ICU shall

                                       23
<PAGE>

                                                                    Confidential

create a development plan in a timely manner for such defined product, which
development plan shall include a detailed timetable and budget, and shall
deliver such development plan to Hospira in writing for approval, which approval
shall not be unreasonably withheld. The development plans, collectively, shall
provide for spending by ICU of, and ICU shall actually spend, the amounts listed
on Exhibit 7.1A for the time periods set forth on such exhibit, in the expense
categories that are listed on Exhibit 7.1A (the "Development Spending"). If, at
ICU's request, Hospira provides Hospira research and development personnel to
assist in the development efforts, ICU shall reimburse Hospira with respect to
such personnel during the period they provide such assistance as set forth in
Exhibit 7.1A.

            (b) If at any time during the initial five Contract Years the
Parties are unable to agree on product development priorities and product
definitions for the entire Development Spending, then the Development Spending
shall be allocated as described on Exhibit 7.1A. ICU shall develop, execute and
spend under a development plan for such Hospira-defined products as set forth in
Section 7.1(a) with respect to mutually defined products.

      7.2 Progress. ICU will use commercially reasonable efforts to execute the
development plan approved by Hospira in accordance with Section 7.1(a) or (b)
and will keep Hospira apprised of its progress, including providing Hospira with
milestone achievement status and spending reports, as reasonably requested by
Hospira. Hospira shall have Audit Rights with respect to the applicable
financial records of ICU to confirm compliance with the spending requirements of
Section 7.1(a) or (b).

      7.3 New Joint Products. If ICU develops a New Joint Product, such New
Joint Product shall be a "Product" under this Agreement and ICU shall
manufacture, and Hospira shall purchase and actively market and sell, such New
Joint Product, all in accordance with the terms of this Agreement.

      7.4 Monitoring Equipment and Software. Hospira shall spend commercially
reasonable amounts to maintain and enhance its Q2TM Plus monitoring equipment,
software and related components; provided, to the extent that marketing the Q2TM
Plus equipment is no longer commercially practicable, Hospira shall use
commercially reasonable efforts to develop, acquire or obtain access to
successor technology or technology that provides the ability to interface with
Third Party patient monitors in order to provide customers with comparable
functionality to the Q2TM Plus.

               ARTICLE 8 - AGREEMENTS RELATING TO OTHER PRODUCTS

      8.1 New Hospira Competitive Products. If Hospira develops or acquires any
New Hospira Competitive Product, Hospira shall offer ICU the right to
exclusively manufacture such New Hospira Competitive Product unless Hospira can
manufacture such New Hospira Competitive Product itself at a Fully Burdened
Manufacturing Cost, or have it manufactured by a Third Party at a price, in
either case less than the price that ICU is willing to offer or match. Hospira
shall provide written notice to ICU of the development of a New Hospira
Competitive Product and the specifications, estimated market potential and such
estimated cost or price for such New Hospira Competitive Product as soon as
reasonably practicable, which shall be prior to the earlier of (i) any filing
for Regulatory Approval for any such New Hospira Competitive Product or (ii) six
months before the estimated first commercial sale of such New Hospira

                                       24
<PAGE>

                                                                    Confidential

Competitive Product if no Regulatory Approval is required. Hospira shall provide
such notice as soon as reasonably practicable for an acquired New Hospira
Competitive Product that is already on the market at time of acquisition. For a
period of 60 days after ICU's receipt of Hospira's written notice, ICU shall
have the right to notify Hospira in writing of ICU's intent to manufacture such
New Hospira Competitive Product in accordance with the terms set forth in this
Section 8.1. Upon receipt by Hospira of such notice, such New Hospira
Competitive Product shall become a "Product" for purposes of this Agreement. If
ICU notifies Hospira that it is not interested in such New Hospira Competitive
Product or fails to give Hospira timely notice of its interest, Hospira shall be
free to manufacture the New Hospira Competitive Product itself or to grant
rights to do so to a Third Party; provided that Hospira shall not enter into an
agreement which grants any rights to such New Hospira Competitive Product to any
Third Party, on terms which, taken as a whole, are more favorable to such Third
Party than those available to ICU hereunder, without first offering such more
favorable terms to ICU. If Hospira offers such terms to ICU pursuant to the
immediately preceding sentence, then ICU's period to elect such more favorable
terms shall be 30 days. All information regarding any New Hospira Competitive
Product shall be Confidential Information. Notwithstanding anything herein to
the contrary, Hospira shall not be required to offer to ICU the right to
manufacture New Hospira Competitive Products that result from Hospira's
acquisition of an ongoing business or a manufacturing plant or that are subject
to a binding agreement with a Third Party at the time of the acquisition of the
New Hospira Competitive Product, but Hospira shall grant manufacturing rights to
ICU for such New Hospira Competitive Products if, and only if, it is
commercially reasonable for Hospira to do so; provided, however, that if Hospira
plans to transfer the manufacture of any New Hospira Competitive Product that
results from its acquisition of a manufacturing facility from such acquired
facility to a Third Party, Hospira shall negotiate in good faith with ICU for
the manufacture of such New Hospira Competitive Product.

      8.2 New ICU Competitive Products. If ICU develops or acquires any New ICU
Competitive Product, ICU shall offer Hospira the right to exclusively market,
sell and distribute such New ICU Competitive Product unless ICU can market, sell
and distribute such New ICU Competitive Product itself, or have a Third Party
market, sell, and distribute such products, in either case at better terms than
Hospira is willing to offer or match. ICU shall provide written notice to
Hospira of the development or acquisition of such New ICU Competitive Product
and the specifications, estimated market potential and proposed pricing for such
New ICU Competitive Product as soon as reasonably practicable, but in any event
prior to the earlier of (i) any filing for Regulatory Approval for a New ICU
Competitive Product, or (ii) six months before the estimated first commercial
sale of a New ICU Competitive Product if no Regulatory Approval is required. For
a period of 60 days after Hospira's receipt of ICU's written notice, Hospira
shall have the right to notify ICU in writing of Hospira's intent to market such
New ICU Competitive Product in accordance with ICU's proposed terms and under
the terms of a new agreement. Upon consummation of a new agreement, such New ICU
Competitive Product shall become a "Product" for purposes of this Agreement. If
Hospira notifies ICU that it is not interested in such New ICU Competitive
Product or fails to give ICU timely notice of its interest, or the Parties fail

                                       25
<PAGE>

                                                                    Confidential

to reach agreement after good faith negotiations, ICU shall be free to
commercialize the New ICU Competitive Product itself or to grant rights to do so
to a Third Party; provided that ICU shall not enter into an agreement which
grants any rights to such New ICU Competitive Product to any Third Party, on
terms which, taken as a whole, are more favorable to such Third Party than those
available to Hospira hereunder, without first offering such more favorable terms
to Hospira. If ICU offers such terms to Hospira pursuant to the immediately
preceding sentence, then Hospira's period to elect such more favorable terms
shall be 30 days. All information regarding any New ICU Competitive Product
shall be Confidential Information. Notwithstanding anything herein to the
contrary, (i) ICU shall not be required to negotiate with or make the offer to
Hospira contemplated above with respect to New ICU Competitive Products that
result from ICU's acquisition of an ongoing business that has a marketing and
sales organization, but ICU shall grant exclusive marketing, sales, and
distribution rights to Hospira for such New ICU Competitive Products if, and
only if, it is commercially reasonable for ICU to do so and (ii) ICU shall not
be required to negotiate with or make the offer to Hospira contemplated above
with respect to any New ICU Competitive Product if such acquired New ICU
Competitive Product is subject to a contractual arrangement with a Third Party
at the time of the acquisition that prevents such granting of such rights until
such time as the term of any such contractual arrangement expires.

      8.3 Derivative Products. Either during the Term or thereafter, ICU shall
not have the right, either directly or through Third Parties, to manufacture,
sell, distribute or market ICU Derivative Products without the prior written
consent of Hospira. Either during the Term or thereafter, Hospira shall not have
the right, either directly or through Third Parties, to manufacture, sell,
distribute or market Hospira Derivative Products without the prior written
consent of ICU.

                ARTICLE 9 - TRADEMARKS AND INTELLECTUAL PROPERTY

      9.1 General. Each Party agrees to notify the other Party if it becomes
aware of (i) any actual or potential Third Party infringement of the other
Party's intellectual property rights (including patents, know-how and
trademarks) relevant to the Products or (ii) any Third Party claim that ICU's
manufacture and sale of the Products to Hospira hereunder or Hospira's sale of
Products to customers infringes any Third Party intellectual property rights.

      9.2 Intellectual Property License. Subject to the terms of this Agreement,
Hospira hereby grants to ICU a limited, non-transferable, fully paid license
(without the right to sublicense) to use all intellectual property rights
(including patents, know-how, and trademarks) owned by Hospira that are
necessary to manufacture the Products, solely for the purpose of manufacturing
the Products in accordance with the terms of this Agreement. Except as otherwise
contemplated by this Agreement, during the Term, Hospira shall not grant to any
Third Party a new license to use such intellectual property rights for the
manufacturing of products that are competitive with Products.

      9.3 Jointly Developed Intellectual Property. ICU and Hospira mutually
acknowledge that personnel employed by both ICU and Hospira may collaborate in
an effort to improve and develop Products, whether or not such effort is funded
by Development Spending. Accordingly, ICU and Hospira agree that in the event
improvements to Products arise (whether patentable or not) as a result of such

                                       26
<PAGE>

                                                                    Confidential

collaboration and such improvements were not developed independently by either
Party as evidenced by the written records of the inventing Party, the ownership
rights of both Parties in and to any such improvements shall be shared equally
by the Parties in the case of non-patentable improvements. In the case of
patentable improvements, patent applications or patents covering such jointly
developed improvements shall be governed by patent laws of the United States. If
either Party wishes to pursue patent protection for jointly developed
intellectual property, the Party wishing to obtain any such patent protection in
a particular country shall provide the other Party with at least 30 days prior
written notice thereof and discuss in good faith with the other Party the
appropriate patent filing and prosecution strategy. Except as otherwise agreed
in writing by the Parties, the filing Party shall bear the entire cost of
filing, prosecution, issuance and maintenance of such patent in such country
using counsel of its own choice; provided, however, that if both Parties agree
in writing to jointly file any such patent, with respect to all such matters
involving such patent, each Party shall bear one-half (1/2) of such costs and
shall also mutually agree upon the counsel designated to handle such matters.
The Parties hereby grant to each other a limited, non-transferable, fully paid
license (without the right to sublicense, except as necessary for Hospira to
market and sell the Products) to use all intellectual property subject to this
Section 9.3 solely in connection with the manufacture of the Products in
accordance with the terms of this Agreement. During the Term, neither Party
shall utilize any jointly developed intellectual property for the manufacture,
use, or sale of any product that is not a Product; provided that if either Party
wishes to use any improvements subject to this Section 9.3 to develop or
manufacture products other than the Products, then the Parties shall negotiate
in good faith to provide commercially reasonable compensation to the other
Party.

      9.4 Independent Intellectual Property. Any improvements related to the
Products (whether such improvements are patentable or not) developed by a Party
independently, with or without any of the Development Spending, shall be owned
by that Party and made available during the Term to the other Party solely for
the manufacture and purchase of Products under this Agreement, as the case may
be, at no additional cost beyond the Transfer Price for the applicable Product
or the price agreed upon pursuant to Sections 8.1 and 8.2. The owner of such
independent intellectual property shall not be prohibited from exploiting such
intellectual property apart from this Agreement, provided such exploitation does
not otherwise violate the terms of this Agreement, including Sections 8.1, 8.2
and 8.3 hereof.

      9.5 RESERVED

      9.6 Trademarks.

            (a) Grant of License. Subject to the terms and conditions of this
Agreement, ICU hereby grants to Hospira a limited, non-exclusive,
non-transferable, fully paid license (without the right to sublicense) to use
the ICU Marks during the Term solely for the purposes of fulfilling its
obligations under this Agreement and Hospira hereby grants to ICU a limited,
non-exclusive, non-transferable, fully paid license (without the right to
sublicense) to use the Hospira Marks during the Term solely for the purposes of
fulfilling its obligations under this Agreement.

            (b) Use of Marks. Except as expressly provided in this Section 9.6,
Hospira shall not use the ICU Marks in any other manner without the prior
written consent of ICU. Under no circumstances shall ICU use the Hospira Marks
except to produce Products for sale to Hospira. Each Party shall retain all
rights to its own intellectual property. All uses by Hospira and ICU of the
other Party's trademarks shall be in full compliance with all applicable Laws.

                                       27
<PAGE>

                                                                    Confidential

            (c) Hospira Ownership. ICU acknowledges and agrees that Hospira is
the sole and exclusive owner of all right, title and interest in and to
Hospira's trademarks. All goodwill associated with the Hospira trademarks shall
inure to the benefit of Hospira. ICU shall notify Hospira in writing of any
infringements or imitations by Third Parties of the Hospira trademarks of which
ICU becomes aware.

            (d) ICU Ownership. Hospira acknowledges and agrees that ICU is the
sole and exclusive owner of all right, title and interest in and to the ICU
trademarks. All goodwill associated with the ICU trademarks shall inure to the
benefit of ICU. Hospira shall notify ICU in writing of any infringements or
imitations by Third Parties of the ICU trademarks of which Hospira becomes
aware.

             ARTICLE 10 - CORPORATE REPRESENTATIONS AND WARRANTIES

      10.1 Hospira Representations and Warranties. Hospira hereby represents and
warrants to ICU, as of the date hereof, that:

            (a) Hospira has full right, power and authority to enter into this
Agreement and to perform its obligations under this Agreement;

            (b) this Agreement has been duly executed by an authorized officer
of Hospira and constitutes a legal, valid and binding obligation of Hospira,
enforceable in accordance with its terms except as enforceability may be limited
by applicable bankruptcy, insolvency, moratorium, reorganization or similar laws
affecting creditor's rights generally and general equitable principles;

            (c) no consents, authorizations or approvals which Hospira has not
previously obtained are necessary for Hospira to enter into this Agreement and
perform all of Hospira's obligations hereunder;

            (d) this Agreement does not and will not conflict with or violate
Hospira's corporate charter and by-laws;

            (e) this Agreement does not and will not conflict with, violate,
breach or constitute a default under any other Hospira contractual, statutory or
regulatory obligation; and

            (f) there is no claim, investigation, suit, action or proceeding
pending or, to the knowledge of Hospira, expressly threatened, against Hospira
before or by any governmental entity or Third Party that would impair the
ability of Hospira to perform any obligation under this Agreement or prevent or
materially delay or alter the consummation of any or all of the transactions
contemplated hereby.

                                       28
<PAGE>

                                                                    Confidential

      10.2 ICU Representations and Warranties. ICU hereby represents and
warrants to Hospira, as of the date hereof, that:

            (a) ICU has full right, power and authority to enter into this
Agreement and to perform its obligations under this Agreement;

            (b) this Agreement has been duly executed by an authorized officer
of ICU and constitutes a legal, valid and binding obligation of ICU, enforceable
in accordance with its terms except as enforceability may be limited by
applicable bankruptcy, insolvency, moratorium, reorganization or similar laws
affecting creditor's rights generally and general equitable principles;

            (c) no consents, authorizations or approvals which ICU has not
previously obtained are necessary for ICU to enter into this Agreement and
perform all of ICU's obligations hereunder;

            (d) this Agreement does not and will not conflict with or violate
ICU's corporate charter and by-laws;

            (e) this Agreement does not and will not conflict with, violate,
breach or constitute a default under any other ICU contractual, statutory or
regulatory obligation; and

            (f) there is no claim, investigation, suit, action or proceeding
pending or, to the knowledge of ICU, expressly threatened, against ICU before or
by any governmental entity or Third Party that would impair the ability of ICU
to perform any obligation under this Agreement or prevent or materially delay or
alter the consummation of any or all of the transactions contemplated hereby.

                          ARTICLE 11 - INDEMNIFICATION

      11.1 Hospira's Indemnification of ICU. Hospira shall indemnify and hold
ICU, its Affiliates, and all of their respective officers, directors, employees,
agents and representatives, harmless from and against all losses, liabilities,
costs and expenses (including reasonable attorney's fees) (collectively,
"Liabilities") related to this Agreement and asserted by Third Parties to the
extent such arise out of or are attributable to: (a) any negligent or wrongful
act or omission on the part of Hospira, its employees or agents; (b) any product
defect of a Transferred Product or Transferred Component manufactured at the
Facility during the 180 days immediately following the Effective Date, but only
to the extent that such defect arose directly from adherence to the design of,
specifications for, or manufacturing processes and procedures for, a Product
that was transferred or licensed by Hospira to ICU as of the Effective Date and
was not otherwise due to the negligence or wrongful act or omission on the part
of ICU, its Affiliates, or any of their respective officers, directors,
employees, agents or representatives; provided that Hospira shall provide
indemnification for (A) 100% of any Liabilities arising out of or attributable
to the circumstances described in this clause (b) during the first 45 days
immediately following the Effective Date, (B) 75% of any Liabilities arising out
of or attributable to the circumstances described in this clause (b) during the
period beginning on the 46th day immediately following the Effective Date and

                                       29
<PAGE>

                                                                    Confidential

ending on the 90th day immediately following the Effective Date, (C) 50% of any
Liabilities arising out of or attributable to the circumstances described in
this clause (b) during the period beginning on the 91st day immediately
following the Effective Date and ending on the 150th day immediately following
the Effective Date, and (D) 25% of any Liabilities arising out of or
attributable to the circumstances described in this clause (b) during the period
beginning on the 151st day immediately following the Effective Date and ending
on the 180th day immediately following the Effective Date; (c) any FDA-initiated
audit, inspection or visit to the Facility prior to the Effective Date or during
the 180 days immediately following the Effective Date, but only to the extent
that any such Liability was a direct result of (i) adherence to the quality
systems for manufacture of Transferred Products and Transferred Components
transferred or licensed by Hospira to ICU as of the Effective Date and was not
otherwise due to the negligence or wrongful act or omission on the part of ICU,
its Affiliates, or any of their respective officers directors, employees, agents
and representatives or (ii) the manufacture of such Products by Hospira prior to
the Effective Date; provided that Hospira shall provide indemnification for (A)
100% of any Liabilities arising out of or attributable to the circumstances
described in this clause (c) during the first 45 days immediately following the
Effective Date, (B) 75% of any Liabilities arising out of or attributable to the
circumstances described in this clause (c) during the period beginning on the
46th day immediately following the Effective Date and ending on the 90th day
immediately following the Effective Date, (C) 50% of any Liabilities arising out
of or attributable to the circumstances described in this clause (c) during the
period beginning on the 91st day immediately following the Effective Date and
ending on the 150th day immediately following the Effective Date, and (D) 25% of
any Liabilities arising out of or attributable to the circumstances described in
this clause (c) during the period beginning on the 151st day immediately
following the Effective Date and ending on the 180th day immediately following
the Effective Date; (d) any alleged infringement of any Third Party intellectual
property right resulting from the manufacture, use, sale or importation of the
Transferred Products, Transferred Components or New Hospira Competitive
Products, unless such infringement is caused by a manufacturing process utilized
by ICU after the Effective Date that is different from the manufacturing process
utilized by Hospira as of the Effective Date, or is otherwise caused by a change
requested by ICU pursuant to Sections 3.1(a) or (b) hereof; (e) any alleged
infringement of any Third Party intellectual property right resulting from the
manufacture, use, sale, offer for sale or importation of a New ICU Competitive
Product or New Joint Product, if such infringement is related to a change to the
Specifications requested by Hospira pursuant to Section 3.1(a) hereof and is not
otherwise caused by the wrongful act or omission of ICU; or (f) any breach of
any of Hospira's representations, warranties, covenants or obligations under
this Agreement. As the indemnified Party, ICU shall use commercially reasonable
efforts to limit the liabilities for which it is being indemnified hereunder.

      11.2 ICU's Indemnification of Hospira. ICU shall indemnify and hold
Hospira, its Affiliates, and all of their respective officers, directors,
employees, agents and representatives, harmless from and against all Liabilities
related to this Agreement and asserted by Third Parties to the extent such arise
out of or are attributable to: (a) any negligent or wrongful act or omission on
the part of ICU, its employees or agents; (b) any alleged infringement of any
Third Party intellectual property right resulting from the manufacture, use,

                                       30
<PAGE>

                                                                    Confidential

sale, offer for sale or importation of a New ICU Competitive Product or New
Joint Product, unless such infringement is caused by a change to the
Specifications requested by Hospira pursuant to Section 3.1(a) hereof and is not
otherwise caused by the wrongful act or omission of ICU; (c) any alleged
infringement of any Third Party intellectual property right resulting from the
manufacture, use, sale, offer for sale or importation of the Transferred
Products, Transferred Components or New Hospira Competitive Products, if such
infringement is caused by a change requested by ICU pursuant to Section 3.1(a)
or (b) hereof; (d) any breach of any of ICU's representations, warranties,
covenants or obligations under this Agreement; or (e) other than as indemnified
for by Hospira pursuant to Section 11.1(b) or (c) above, the manufacture of the
Products or the use of or lack of safety or efficacy of any Product. As the
indemnified Party, Hospira shall use commercially reasonable efforts to limit
the liabilities for which it is being indemnified hereunder.

      11.3 Notice and Defense. The Party seeking indemnification shall promptly
notify the other Party of any Liabilities for which indemnification is sought.
The indemnified Party shall cooperate fully with the indemnifying Party in the
investigation and defense of any Liability and shall allow the indemnifying
Party to control the defense of any such Liability with counsel reasonably
satisfactory to the indemnified Party. No settlement or compromise shall be made
without the prior written consent of the indemnifying Party, which consent shall
not be unreasonably withheld.

      11.4 Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER
PARTY FOR INDIRECT, EXEMPLARY, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES
RESULTING FROM ANY BREACH OF THIS AGREEMENT, EVEN IF THE PARTY HAS BEEN ADVISED
OF THE POSSIBILITY OF SUCH DAMAGES, AND EACH PARTY HEREBY WAIVES ON BEHALF OF
ITSELF AND ITS AFFILIATES ANY CLAIM FOR SUCH DAMAGES, INCLUDING ANY CLAIM FOR
PROPERTY DAMAGE OR LOST PROFITS, WHETHER ARISING IN CONTRACT OR TORT.

      The foregoing limitations of liability shall not apply to (i) liability
for breaches of confidentiality under Article 12, or (ii) a Party's
indemnification obligations for claims brought by Third Parties.

      11.5 Insurance.

            (a) ICU will procure and maintain, at its own expense, for the Term
of this Agreement, and for a period of time thereafter as set forth herein, the
types of insurance specified below with carriers rated A(VII) or better with A.
M. Best or the equivalent rating from Moody's or S&P:

                  (i) Commercial General Liability including premises
      operations, products and completed operations, blanket contractual
      liability, personal injury and advertising injury including fire legal
      liability for bodily injury and property damage in an amount not less than
      $1,000,000 per occurrence and $2,000,000 in the aggregate;

                  (ii) Excess Liability with a combined single limit in an
      amount of not less than $9,000,000 per occurrence, so that the combined
      total with the insurance described in clause (i) above is at least
      $10,000,000 in the aggregate; and

                                       31
<PAGE>

                                                                    Confidential

                  (iii) All Risk Property Insurance on a replacement cost basis
      for any Specified Components and other Hospira property while under the
      care, custody and control of ICU.

            (b) Hospira and its subsidiaries, affiliates, directors, officers,
employees and agents shall be an additional insured with respect to Commercial
General Liability and Excess Liability coverages and a loss payee with respect
to All Risk Property coverages. Prior to commencement of this Agreement, and
annually thereafter, ICU shall furnish Hospira with certificates of insurance
evidencing the insurance coverages stated above and shall require at least 30
days written notice to Hospira prior to any cancellation, non-renewal or
material change in said coverage. ICU agrees that its insurance shall act as
primary and noncontributory from any other valid and collectible insurance
maintained by Hospira. In no way shall ICU's liability under this Agreement be
limited to what is recovered by insurance.

                          ARTICLE 12 - CONFIDENTIALITY

      12.1 Non-Disclosure. It is recognized by the Parties that during the Term
the Parties may exchange Confidential Information. Hospira agrees that it shall
not disclose Confidential Information received from ICU, and shall not use
Confidential Information disclosed to it by ICU for Hospira's benefit (other
than in the performance of its obligations hereunder) or for the benefit of any
Third Party. ICU agrees that it shall not disclose Confidential Information
received from Hospira, and shall not use Confidential Information disclosed to
it by Hospira for ICU's benefit (other than in the performance of its
obligations hereunder) or for the benefit of any Third Party. The obligations of
the Parties relating to non-disclosure of Confidential Information shall expire
five years after the termination of this Agreement.

      12.2 Public Announcements.

            (a) No press release related to this Agreement or the transactions
contemplated herein, or other announcement to the customers or suppliers of
Hospira, will be issued without the joint approval of Hospira and ICU, except:
(i) any public disclosure which Hospira or ICU in its good faith judgment
believes is required by any Laws or by any stock exchange or national stock
market on which its securities are listed (in which case the Party making the
disclosure will use its commercially reasonable efforts to consult with the
other Party prior to making any such disclosure); (ii) that Hospira may make
such an announcement to its employees; and (iii) as provided in Section 12.2(b)
below.

            (b) As soon as practical after the execution of this Agreement, the
Parties will issue the joint press release set forth on Schedule 6.10(b) of the
Asset Purchase Agreement. The Parties will use the question and answer document
set forth on Schedule 6.10(b) of the Asset Purchase Agreement when making public
statements related to this Agreement.

            (c) The Parties acknowledge that ICU is required to describe this
Agreement in, and provide copies of this Agreement with, various filings with
the Securities and Exchange Commission. ICU agrees to use reasonable efforts to
seek confidential treatment of any market competitive information contained in
this Agreement.

                                       32
<PAGE>

                                                                    Confidential

      12.3 Employee and Consultant Obligations. Each Party represents, warrants
and covenants that, unless prohibited by or inconsistent with applicable Laws,
all of its employees, officers, consultants and advisors who are supporting the
performance of its obligations under this Agreement shall have executed
agreements, or have existing obligations under law, requiring assignment to such
Party of all intellectual property made during the course of and as the result
of their association with such Party and obligating such employee, officer,
consultant or advisor to maintain as confidential such Party's Confidential
Information as well as any confidential information of a Third Party which such
Party may receive. Each Party represents and warrants that to its knowledge,
none of its employees who are or will be involved in the performance of
obligations hereunder are, as a result of the nature of such obligations to be
conducted by the Parties as set forth herein, in violation of any covenant in
any contract with a Third Party relating to non-disclosure of proprietary
information, non-competition or non-solicitation. Each Party represents and
warrants that, to its knowledge, none of its employees are in breach of any
agreement with any Third Party which would affect such Party's obligations under
this Agreement.

                       ARTICLE 13 - TERM AND TERMINATION

      13.1 Term. Unless earlier terminated, the Term shall commence on the
Effective Date and shall expire on December 31, 2024 (the "Term").

      13.2 RESERVED

      13.3 Termination For Cause.

            (a) Notice of Breach. A Party may terminate this Agreement by giving
the other Party 60 days' prior written notice of such termination if such other
Party: (i) appoints a receiver, executes an assignment for the benefit of
creditors or files or otherwise becomes subject to bankruptcy or insolvency
proceedings that are not discharged within 90 days; or (ii) materially breaches
this Agreement and fails to cure such breach within 60 days of receiving notice
thereof. In no event shall a Party's right to cure an alleged material breach be
prejudiced by such Party's seeking dispute resolution under Section 14.4 as to
whether a material breach has occurred. Any termination under this Section 13.3
shall be without prejudice to any other legal or equitable rights the
terminating Party may have.

            (b) Negotiation Period. Upon receipt of notice of termination for an
uncured material breach pursuant to Section 13.3(a)(ii) above, the Parties shall
engage in good faith negotiations between their respective CEOs (or their
designees) during a period of 28 calendar days following receipt of the notice.

            (c) Initiation of ADR Proceeding Regarding Termination. If the
matter has not been resolved within such 28 calendar days, or if the Parties
fail to meet within such 28 calendar days, the Party seeking termination may
initiate an ADR proceeding (beginning with Paragraph 1 of Exhibit 14.4) with
respect to whether the other Party has materially breached this Agreement and
failed to timely cure such breach, entitling the non-breaching Party to
termination pursuant to Section 13.3(a)(ii).

                                       33
<PAGE>

                                                                    Confidential

            (d) Special Transaction. The Parties agree that upon a termination
of this Agreement for Hospira's material breach, the Parties shall effect the
Special Transaction unless Hospira can establish in the ADR proceeding that
effecting the Special Transaction would be unfair under the circumstances. The
Parties agree that the Special Transaction is not intended to be a penalty, but
rather to be a fair means of terminating their relationship under this Agreement
under the circumstances described above.

      13.4 Termination by Mutual Agreement. The Parties may mutually agree in
writing to terminate this Agreement.

      13.5 Certain Effects of Termination.

            (a) Delivery of Previously Ordered Products. Upon any termination of
this Agreement by ICU, Hospira shall, at its option, be entitled to have
delivered the Products ordered prior to such termination pursuant to outstanding
Purchase Orders, or to cancel such outstanding Purchase Orders.

            (b) Inventory. Upon any termination of this Agreement, Hospira may
continue to sell the Products manufactured by ICU under the terms and conditions
of this Agreement until any inventory of Products owned by Hospira has been
sold. ICU shall destroy all material in its inventory reflecting Hospira's
trademarks.

            (c) Confidential Information. Upon any termination of this
Agreement, each Party shall cease using all Confidential Information of the
other Party. Upon either Party's request, the other Party shall destroy or
return to its owner all written and tangible Confidential Information; provided,
however, that each Party may keep one copy of such Confidential Information for
archival and compliance purposes only.

            (d) Manufacturing Documentation and Intellectual Property Upon
Non-Breach Termination (Hospira's Rights). Upon the expiration of this Agreement
under Section 13.1, or by mutual agreement of the Parties under Section 13.4,
except to the extent necessary to comply with clause (a) above, (i) ICU shall
have no further rights to any intellectual property rights owned solely by
Hospira, (ii) ICU shall transfer to Hospira, and have no further rights to, all
manufacturing processes, documentation, specifications, know-how, intellectual
property and Regulatory Approvals necessary for the manufacture and sale of the
Transferred Products, Transferred Components and New Hospira Competitive
Products, and (iii) ICU shall provide a copy to Hospira of all manufacturing
processes, documentation, specifications, know-how, intellectual property and
Regulatory Approvals for the New Joint Products to enable Hospira to manufacture
and sell such New Joint Products and, if there is intellectual property solely
owned by ICU that is necessary to manufacture or sell New Joint Products, then
ICU shall grant to Hospira a license to use all of its intellectual property
rights that are necessary to manufacture and sell the New Joint Products on
commercially reasonable terms to be negotiated in good faith by the Parties;
provided that ICU shall not be required to grant licenses or transfer the items
described in clauses (ii) and (iii) above that relate to ICU proprietary
components or products, but shall sell such components or products to Hospira on
commercially reasonable terms.

                                       34
<PAGE>

                                                                    Confidential

            (e) Manufacturing Documentation and Intellectual Property Upon
Non-Breach Termination (ICU's Rights). Upon the expiration of this Agreement
under Section 13.1 or termination by mutual agreement of the Parties under
Section 13.4, if there is intellectual property solely owned by Hospira that is
necessary to manufacture or sell New Joint Products, then Hospira shall grant to
ICU a license to use all of its intellectual property rights that are necessary
to manufacture and sell the New Joint Products on commercially reasonable terms
to be negotiated in good faith by the Parties.

            (f) Manufacturing Documentation and Intellectual Property Upon
Material Breach Termination (Hospira's Rights). In the event that this Agreement
is terminated by Hospira for material breach under Section 13.3 (a) above,
except to the extent necessary to comply with clause (a) above, (i) ICU shall
have no further rights to any intellectual property rights owned solely by
Hospira, (ii) ICU shall transfer to Hospira, and have no further rights to, all
manufacturing processes, documentation, specifications, know-how, intellectual
property and Regulatory Approvals necessary for the manufacture and sale of the
Transferred Products, Transferred Components and New Hospira Competitive
Products, and (iii) ICU shall provide a copy to Hospira of all manufacturing
processes, documentation, specifications, know-how, intellectual property and
Regulatory Approvals for the New Joint Products to enable Hospira to manufacture
and sell such New Joint Products and, if there is intellectual property solely
owned by ICU that is necessary to manufacture or sell New Joint Products, then
ICU shall grant to Hospira a non-exclusive, royalty-free license to use all of
its intellectual property rights that are necessary to manufacture and sell the
New Joint Products; provided that ICU shall not be required to grant licenses or
transfer the items described in clauses (ii) and (iii) above that relate to ICU
proprietary components or products, but shall sell such components or products
to Hospira on terms that are commercially reasonable under the circumstances.

            (g) Trademarks. Upon expiration or termination of this Agreement,
except to the extent necessary to comply with clause (a) above, ICU shall
immediately discontinue its use of the Hospira trademarks, and Hospira shall
discontinue its use of the ICU trademarks once all inventory of Products has
been sold.

            (h) Survival. The following Articles or Sections shall survive the
termination or earlier expiration of this Agreement: Article 1 (Definitions),
Article 9 (Trademarks and Intellectual Property), Article 11 (Indemnification),
Article 12 (Confidentiality), Section 8.3 (Derivative Products), Section 13.3(d)
(Special Transaction), Section 13.5 (Certain Effects of Termination), Section
14.3 (Notices), Section 14.4 (Dispute Resolution), Section 14.6 (Governing Law)
and Section 14.8 (Assignment).

                           ARTICLE 14 - MISCELLANEOUS

      14.1 Force Majeure. Subject to Hospira's rights under Section 3.2(c) (i),
(ii) and (iii) (Failure to Supply) any delay in the performance of any of the
duties or obligations of either Party hereto (except the payment of money) shall
not be considered a breach of this Agreement and the time required for
performance shall be extended for a period equal to the period of such delay;

                                       35
<PAGE>

                                                                    Confidential

provided that such delay has been caused by or is the result of any acts of God,
acts of public enemy, insurrections, riots, embargoes, labor disputes, including
strikes, lockouts, job actions, or boycotts, fires, explosions, earthquakes,
floods, shortages of energy, order by any governmental agency or
instrumentality, or other unforeseeable causes beyond the control and without
the fault or negligence of the Party so affected. The Party so affected shall
give prompt notice to the other Party of such cause, and its expected duration.
In such event, the Parties shall meet promptly to determine an equitable
solution to the effects of any such event, and the Party claiming the force
majeure event shall thereafter take whatever reasonable steps are necessary to
relieve the effect of such cause as rapidly as possible.

      14.2 Independent Contractors. The Parties hereto are independent
contractors. Nothing contained in this Agreement shall be construed to
constitute a Party as a partner, agent or joint venturer with the other Party or
as a participant in a joint or common undertaking with the other Party. Each
Party shall be individually responsible for its own obligations and liabilities
as herein provided. Neither Party shall be under the control or shall be deemed
to control the other Party. Neither Party shall be the agent of or have the
right or power to bind the other Party without such Party's express written
consent, except as may be expressly provided in this Agreement.

      14.3 Notices. All notices hereunder shall be delivered personally; by
registered or certified mail, postage prepaid; by facsimile with a confirmation
copy sent by registered or certified mail, postage prepaid; or by overnight
courier service, to the following addresses of the respective Parties:

      If to Hospira:  Hospira, Inc.
                      Building H1; Department 0960
                      275 N. Field Drive
                      Lake Forest, IL 60045-2579

                      Attention: Chief Executive Officer
                                 Facsimile No.: (224) 212-3262

      With a copy to: Hospira, Inc.
                      Building H1; Department NLEG
                      275 N. Field Drive
                      Lake Forest, IL 60045-2579

                      Attention: General Counsel
                                 Facsimile No.: (224) 212-2088

      If to ICU:      ICU Medical, Inc.
                      951 Calle Amanecer
                      San Clemente, California 92673

                      Attention: Chief Financial Officer
                                 Facsimile No.: 949-366-8368 and (949) 366-4264

                                       36
<PAGE>

                                                                    Confidential

      With a copy to: Heller Ehrman White & McAuliffe
                      601 South Figueroa Street
                      40th Floor
                      Los Angeles, California 90017

                      Attention: Stephen E. Newton
                                 Facsimile No.: (213) 614-1868

Notices shall be effective upon receipt if personally delivered or delivered by
facsimile, on the third Business Day following the date of mailing or on the
first Business Day following deposit with an overnight courier service. A Party
may change its address listed above by notice to the other Party.

      14.4 Dispute Resolution. The Parties recognize that bona fide disputes may
arise which relate to the Parties' rights and obligations under this Agreement.
The Parties agree that any such dispute shall be resolved by Alternative Dispute
Resolution ("ADR") in accordance with the procedures set forth on Exhibit 14.4.

      14.5 Headings. The section and other headings contained in this Agreement
are for reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement.

      14.6 Governing Law. The validity, construction and performance of this
Agreement shall be governed by the laws, without regard to the laws as to choice
or conflict of laws, of the State of New York.

      14.7 Entire Agreement. This Agreement, including the Exhibits and
Schedules, embodies the entire agreement and understanding between the Parties
pertaining to the subject matter hereof, and supersedes all prior agreements,
understandings, negotiations, representations and discussions, whether verbal or
written, of the Parties, pertaining to that subject matter. There are no
promises, terms, conditions or obligations of the Parties pertaining to that
subject matter other than as contained in this Agreement. Notwithstanding the
foregoing, the Parties acknowledge that they have entered into other agreements
pertaining to other subject matters, including the Asset Purchase Agreement and
the Transaction Documents (as defined in the Asset Purchase Agreement). All
Schedules and Exhibits to this Agreement constitute an integral part of this
Agreement as if fully written herein.

      14.8 Assignment.

            (a) Neither Party shall assign this Agreement or any part hereof
without the prior written consent of the other Party; provided, however, that
(i) Hospira may assign this Agreement in whole or in part without consent of ICU
to a wholly-owned subsidiary of Hospira; provided that any such assignment shall
not release Hospira from its obligations hereunder; (ii) Hospira may assign this
Agreement, in whole or in part, without such consent in connection with the
assignment, transfer, sale or spin-off to a Third Party of substantially its
entire business to which this Agreement pertains, the sale of a product line, or

                                       37
<PAGE>

                                                                    Confidential

in the event of its merger or consolidation with another company; (iii) ICU may
assign this Agreement in whole or in part without such consent to a wholly-owned
subsidiary of ICU; provided that any such assignment shall not release ICU from
its obligations; and (iv) ICU may assign this Agreement without such consent in
connection with its merger or consolidation with another company or the
assignment, sale, transfer or spin-off to a Third Party of all or substantially
all of its assets. No assignment shall relieve any Party of responsibility for
the performance of any accrued obligation which such Party then has hereunder.

            (b) In the event of a Hospira Change of Control Event, Hospira or
its successor shall devote sales, marketing and promotion personnel to its sales
and marketing responsibilities hereunder as provided in Exhibit 14.8. If Hospira
or its successor fails to fulfill its obligation under this Section 14.8(b),
such failure shall be considered a material breach of this Agreement. If such
material breach, or any other material breach of this Agreement following a
Hospira Change of Control Event, is not cured after expiration of the applicable
notice and cure period under Article 13 (Term and Termination), ICU shall be
entitled to non-exclusive rights to market and sell the Products with all of the
rights provided in Section 6.1. If ICU elects to terminate this Agreement as a
result of such material breach, ICU shall (i) be entitled to non-exclusive
rights to market and sell the Products with all of the rights provided in
Section 6.1 and (ii) be entitled to exercise all of its legal rights and
remedies at law and equity against such successor as a result of the successor's
material breach, including rights pursuant to Section 13.5 hereof.

            (c) In the event of an ICU Change of Control Event, ICU or its
successor shall devote field-based technical and product sales support
specialists to assist Hospira with its duties under Section 6.1 as provided on
Exhibit 14.8; provided that, ICU shall not be required to provide technical and
product sales support specialists with respect to Surgicare Products. Hospira
shall have Audit Rights to confirm compliance with this Section 14.8(c).

      14.9 Binding Effect. The provisions of this Agreement shall bind and inure
to the benefit of the Parties and their respective successors and permitted
assigns.

      14.10 Parties in Interest. Nothing in this Agreement, expressed or
implied, is intended to confer on any Person or entity other than Hospira and
ICU any right or remedy under or by reason of this Agreement.

      14.11 Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original, but all of which
together will constitute a single agreement.

      14.12 Amendments and Waiver. This Agreement may be amended, modified or
supplemented only by a writing executed by each of the Parties. Any Party may in
writing waive any provision of this Agreement to the extent such provision is
for the benefit of the waiving Party. No action taken pursuant to this
Agreement, including any investigation by or on behalf of any Party, shall be
deemed to constitute a waiver by that Party of its or any other Party's

                                       38
<PAGE>

                                                                    Confidential

compliance with any representations or warranties or with any provisions of this
Agreement. No waiver by any Party of a breach of any provision of this Agreement
shall be construed as a waiver of any subsequent or different breach, and no
forbearance by a Party to seek a remedy for noncompliance or breach by another
Party shall be construed as a waiver of any right or remedy with respect to such
noncompliance or breach.

      14.13 Severability. The invalidity or unenforceability of any particular
provision of this Agreement shall not affect the other provisions, and this
Agreement shall be construed in all respects as if any invalid or unenforceable
provision were omitted.

                                       39
<PAGE>

                                                                    Confidential

IN WITNESS WHEREOF, the Parties have caused this Agreement to be signed by their
duly authorized representatives on the date first above written.

                                                  ICU MEDICAL, INC.

                                                  By: /s/ George A. Lopez, M.D.
                                                      --------------------------
                                                  Name: George A. Lopez, M.D.
                                                  Title: President & CEO

                                                  HOSPIRA, INC.

                                                  By: /s/ Christopher B. Begley
                                                      --------------------------
                                                  Name: Christopher B. Begley
                                                  Title: Chief Executive Officer

  (Signature Page to Manufacturing Commercialization and Development Agreement)

                                       S-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00084-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00084-of-00352.parquet"}]]